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The heart has been considered a post-mitotic organ incapable of regeneration upon 
injury. Recent findings suggest that the heart contains cardiac progenitor cells 
(CPCs) with the potential to give rise to cardiovascular cells. CPCs are currently 
under clinical investigation aiming at cell-based induction of heart regeneration in 
patients with myocardial infarction related injury. The mechanisms of action 
underlying the reported beneficial effects of CPCs remain for the most part elusive. 
This study was designed to enhance our knowledge on CPC biological activity. By 
making use of engineered heart muscle (EHM) constructed from cardiomyocytes, 
fibroblasts and CPCs in a collagen type 1 hydrogel the aim was to simulate a three-
dimensional heart muscle environment as closely as possible. Different types of 
mouse and human CPCs were investigated and found to be mesenchymal cells 
distinct from fibroblasts. Transcriptome profiling suggested a pericyte phenotype 
within the human CPC population. Despite the apparent differences in cell 
phenotype, CPCs and fibroblast supported the assembly of cardiomyocytes into 
macroscopically contracting EHM. Evidence for CPC transdifferentiation in EHM 
could not be obtained. Novel EHM models of hypoxia/reoxygenation and chronic 
hypoxia damage were developed and used to study potential cardio-protective 
effects of CPCs. Surprisingly, these experiments revealed that hypoxia/reoxygenation 
damage could be attenuated by fibroblasts, but not by CPCs. This effect appeared to 
be mediated by the release of cell protective growth factors and cytokines from 
fibroblasts. Conversely, transcriptome profiling suggested angiogeneic and immune 
modulatory activity in CPCs, which may not be effective in a vascular and leukocyte-
free EHM. The cell context specific biological activity of CPCs was further exemplified 
by studies in EHM tri-cultures composed of cardiomyocytes, fibroblasts and CPCs. 
Only tricultures with CPCs were protected from chonic hypoxia. Finally, to in the 
future be able to visualize the oxygenation level in cardiomyocytes, a transgenic 
hypoxia reporter was established. In summary, CPCs exhibited a distinct phenotype 
from fibroblasts. It appeared that CPCs require a specific mutlicellular context to 
exhibit protective effects upon hypoxia. EHM-hypoxia injury tools and a transgenic 
hypoxia reporter were developed to facilitate future organoid studies on cardio-
protection. 
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1  Introduction 
Myocardial infarction causes the loss of approximately 1 billion cardiomyocytes, 
which are not regenerated, but replaced by non-contractile scar tissue (Gerbin and 
Murry 2015). The associated loss of function is typically at first compensated by a 
hypertrophic response, which finally results in additional cardiomyocyte death and 
whole organ failure (Mill et al. 2011, Zangi et al. 2013). Therapeutic strategies to 
reduce cardiomyocyte death, regenerate the infarcted myocardium and prevent 
progression to heart failure are clearly needed in light of the high mortality in affected 
patients (Yancy et al. 2013). 
1.1 Evidence for cardiomyocyte renewal in the postnatal heart 
The embryonic heart grows through proliferation of cardiomyocytes. Fetal 
cardiomyocytes in the human heart start to withdraw from the cell cycle. Shortly after 
birth, most of the cardiomyocytes are considered post-mitotic; subsequent 
cardiomyocyte growth is by hypertrophy (Laflamme and Murry 2011). Over the recent 
years, a number of studies suggested de novo cardiomyogenesis challenging the 
view that the heart is a static organ (Raphael Rubin 2008). Elegant carbon dating 
studies in human hearts identified very low DNA-replication (lifetime average of 
<1%/year), arguing against significant self-renewal of the heart (Bergmann et al. 
2009, Bergmann et al. 2015). Cardiomyocytes shortly after birth showed the highest 
cell cycle activity, which then decreases with age (Bergmann et al. 2015, Senyo et al. 
2013).  
1.2 Origin of new cardiomyocytes in the postnatal heart 
Identification of cycling cardiomyocytes or progenitors with cardiomyogenic potential 
in the adult heart would open the door for targeted stimulation of these cells. In lower 
vertebrates, such as zebrafish and neonatal mice (1-day old), the heart is capable of 
fully regenerating, which is mediated by the proliferation of pre-existing 
cardiomyocytes (Porrello et al. 2011). Given the fact that the regenerative response 
declines in the adult mammalian heart (Figure 1) (Laflamme and Murry 2011), 




achieve myocardial remuscularization (Bersell et al. 2009, Engel et al. 2006, Hassink 
et al. 2008, Kuhn et al. 2007).  
Figure 1. Heart regenerative response 
in mammalian heart. Embryonic stage: 
cardiomyocytes undergo cell-cycle entry 
and repopulate the heart. Neonatal stage: 
cardiomyocyte proliferation and 
angiogenesis as the two main mechanisms 
involved in complete regeneration of 
neonatal mouse heart following injury. 
Adult stage: insufficient cardiomyocyte 
proliferation and extracellular matrix 
deposition after injury. Schematic adapted 
from Uygur et al. (2016). 
Genetic fate mapping strategies 
based on the expression of 
fluorescence reporter genes in 
specific cell types are powerful 
tools to track the origin of new 
cardiomyocytes formed during 
physiological and pathological 
conditions (Hsieh et al. 2007). 
Differential labeling of endogenous 
cardiomyocytes at a given time 
point indicated no change in the percentage of pre-existing cardiomyocytes during 
physiological aging, suggesting that non-cardiomyocytes do not contribute to heart 
development under normal conditions (Hsieh et al. 2007). Evidence for DNA-
replication and cell cycle activity in resident adult cardiomyocytes (genetically 
labeled) (Malliaras et al. 2013, Senyo et al. 2013) and unambiguously labeling of 
dividing cardiomyocytes with alternative fate-mapping approaches, such as mosaic 
analysis with double markers (MADM) (Ali et al. 2014), supported the hypothesis that 
endogenous cardiomyocytes are the main source of cardiomyocyte turnover under 
physiological conditions, albeit in a very low amount (0.1% of total cardiomyocytes) 




compelling evidence for postnatal cardiomyogenesis via proliferation of endogenous 
cardiomyocytes; however, these rare events cannot be considered of relevance for 
myocardial regeneration after injury of the adult heart. 
Whether endogenous cardiomyocyte proliferation or remuscularization via progenitor 
cell activation is enhanced under pathological conditions remains a matter of debate. 
Studies, which utilized fate-mapping strategy to label pre-existing cardiomyocytes as 
previously described, demonstrated a dilution in the percentage of labeled pre-
existing cardiomyocytes in the infarcted region of the heart after myocardial infarction 
(Ellison et al. 2013, Hsieh et al. 2007). In addition, Malliaras et al. reported that 
although adult cardiomyocyte cycling increases after myocardial injury, the majority of 
likely proliferating cardiomyocytes are from another cell source, so called progenitor 
cells. Thus, both endogenous cardiomyocytes and cardiac progenitors appeared to 
be involved in the replacement of lost cardiomyocytes (Malliaras et al. 2013). 
Although these studies provided some indirect evidence for new myocyte formation 
from a progenitor source, there is no consensus in the literature on the involved 
mechanisms. For example, in a recent study mass spectrometric analysis of 
cardiomyocytes labeled with 15N-stable isotope revealed that new myocytes were 
mostly originating from adult cardiomyocytes after myocardial infarction, although a 
minor contribution of progenitors could not be excluded (Senyo et al. 2013). 
The discrepancies between different studies might be due to technical reasons. Fate-
mapping strategies of resident cardiomyocytes (Ellison et al. 2013, Hsieh et al. 2007, 
Malliaras et al. 2013) can only provide indirect evidence for cardiac differentiation of 
endogenous progenitor cells. In addition, the number of the cells analyzed by multi-
isotope imaging mass spectrometry (Senyo et al. 2013) may have been too small to 
define the contribution of progenitor-derived cardiomyocytes. The limitation of these 
different techniques could only be addressed by direct and unambiguous labeling of 






1.3 Stem/progenitor cell markers in the heart 
 
c-Kit, also known as v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog 
receptor function has been shown to play a crucial role for the migration, proliferation 
and survival of primordial germ cells, neural-crest-derived melanoblasts and 
hematopoietic precursors during embryo development. Many other organs and 
systems (e.g. skeleton, tooth, brain and neural tube, sensory organs, the respiratory 
system, the digestive system, endocrine organs, the genitoexcretory system and 
circulatory system) have been also found to express c-Kit, but without being 
essentially required for their development (Bernex et al. 1996).  
 
c-Kit receptor belongs to the family of type III receptor tyrosine kinase (RTK), which 
also includes platelet-derived growth factor receptor (PDGFR), the macrophage 
colony stimulating factor receptor (CSFR) and fms related tyrosine kinase 3 (FLT3). 
c-Kit receptor tyrosine kinase structure is characterized by extracellular domain 
comprised of five immunoglobulin-like domains, spanning transmembrane region 
followed by an intracellular part that contains juxtamembrane, tyrosine kinase domain 
1 and 2, which is split by a kinase insert sequence and carboxyterminal tail (Figure 













Figure 2. Schematic representation of c-Kit receptor structure and activation. Stem cell factor 
(SCF) ligand binding and dimerization of c-Kit followed by autophopshorylation on tyrosine residues 





Binding of c-Kit ligand, stem cell factor (SCF) triggers dimerization of c-Kit receptor 
followed by autophosphorylation of the receptor. Highly phosphorylated tyrosine 
residues on the activated c-Kit receptor interact with different Src homology domain 2 
(SH2) or SH3 domain containing adaptor proteins which subsequently coordinate the 
activation of downstream signaling pathways including phosphotidylinositol 3-kinases 
(PI3K)/AKT, phospholipase C (PLC)-γ, mitogen-activated protein kinases (ERK1/2, 
p38, JNK), ERK5 and Janus kinase (JAK)/Signal tansducer and activator of 
transcription (STAT) signal transduction pathways that are involved in cell survival, 
proliferation, migration, differentiation, and angiogenesis (Liang et al. 2013).   
 
Stem cells antigen-1 (Sca-1) is a member of lymphocyte activation protein-6A (Ly-6A) 
gene family and is a glycosylphosphatidylinositol-anchored cell surface protein (GPI-
AP) (van de Rijn et al. 1989). The ligand for Sca-1 has been not characterized yet; 
however there is evidence that Sca-1 is associated with Src family kinase members 
suggesting that Sca-1 functions as a receptor (Stefanova et al. 1991). Sca-1 
expression has been detected in several organs; mostly restricted to endothelial cells 
or vasculature in the heart, brain and liver, in cortical tubes of kidney as well as in 
thymus and spleen (van de Rijn et al. 1989). It is important to note that although Sca-
1 protein has been reported in mouse, a human Sca-1 analogue has not been 
identified yet. Sca-1+ cells in human are considered Sca-1+-like cells that have been 
isolated from the adult human heart based on an anti-mouse Sca-1 antibody (Valente 
et al. 2014). 
 
c-Kit and Sca-1 are two surface proteins reported to be expressed on hematopoietic 
stem cells (HSCs) that show the capacity of self-renewing, giving rise to committed 
progenitors and differentiating into all cell lineages of blood system (Ikuta and 
Weissman 1992, Ito et al. 2003). HSCs are mainly found inside specific 
microenvironments, so called endosteal niche in the bone marrow within the 
trabecular bone. The c-Kit receptor ligand, SCF and C-X-C motif chemokine 12 
(CXCL12; also known as stroma cell-derived factor 1 [SDF-1]) are secreted by 
osteoblasts, mesenchymal stromal cells/fibroblasts and CXCL12-abundant reticular 
(CAR) cells within the endosteal niche to support long-term maintenance of HSCs 
(Figure 3). Furthermore, c-Kit and Sca-1 expression on HSCs and their multipotent 




important for self-renewal, motility and differentiation of the stem/progenitor cells 














Figure 3. Hematopoietic stem cells in bone marrow niche and their activation. Schematic 
adapted from Morrison et al. (2014). 
 
1.4 Evidence for cardiac progenitors in the adult heart 
The first evidence for the existence of stem cells in the adult heart was obtained two 
decades ago in the rat heart with isolation of cells that display mesenchymal stem 
cell (MSC) characteristics differentiating into mesodermal lineages (Warejcka et al. 
1996). Subsequently, cells decorated with c-Kit and Sca-1 protein were identified in 
the heart as putative cardiac stem/progenitor cells from the adult heart (Beltrami et al. 
2003, Oh et al. 2003). Resident cardiac progenitor cells (CPCs) were firstly identified 
based on the expression of tyrosine kinase receptor, c-Kit. Isolated c-Kit+ cardiac 
cells showed partial expression of cardiac transcription factors NK2 homeobox 5 
(Nkx2.5), GATA binding protein 4 (GATA4) and myocyte enhancer factor 2 (MEF2), 
suggesting the presence of a small proportion (7-10%) of cardiac committed 
progenies. They displayed stem cell characteristics, i.e., clonogenic growth, self-
renewing capacity and multipotency with evidence presented for their differentiation 
into cardiomyocytes (α-sarcomeric actin+, cardiac myosin heavy chain+), smooth 
muscle cells (α-smooth muscle actin+), and endothelial cells (von Willebrand factor+) 




addition, direct fluorescence labeling of isolated and in vitro expanded CPCs 
demonstrated that they were able to contribute new myocardium formation upon 
injection into the infarcted region of the heart, giving rise to all three cardiac cells 
mentioned above (Beltrami et al. 2003).  
 
Figure 4. Cardiac progenitor cells residing in the adult heart. Cardiac progenitors cells identified 
based on the cell surface marker expression (e.g. c-Kit, Sca-1), genetic marker expression of 
transcription factors Islet-1 and functional properties such as dye-efflux function (cardiac side 
population cells), cardiosphere formation (cardiosphere cells or cardiosphere derived cells) and colony 
formation (colony forming unit-fibroblasts). Schematic adapted from Kikuchi et al. (2012). 
Following this first study demonstrating the presence of endogenous progenitors in 
the adult heart with the capacity to differentiate into cardiac cells in vitro and in vivo, 
c-kit+ CPCs (Bearzi et al. 2007, Miyamoto et al. 2010, Tallini et al. 2009, Zaruba et al. 
2010) as well as other cardiac progenitors were isolated by several groups based on 
the expression of different stem cell-associated surface markers such as Sca-1 
(Noack et al. 2012, Oh et al. 2003, Uchida et al. 2013, Wang et al. 2006), platelet 
derived growth factor receptor, alpha polypeptide (PDGFRα) (Chong et al. 2013, 
Noseda et al. 2015) or functional characteristics (e.g. cardiosphere formation, efflux 
of DNA binding dye and colony forming unit-fibroblasts) (Davis et al. 2009, Pfister et 
al. 2005) or origin (e.g. epicardium) (Limana et al. 2007) (Figure 4). However, it is 
still ambiguous whether these identified CPCs represent subsets of a common stem 
cell source in the heart with a transiently different phenotype or distinguishable stem 
cell types. The list of some of the defined CPCs so far is represented with their 





  Table 1. Putative CPCs and their phenotype in the adult heart.  
 
1.5 Cardiogenic potential of endogenous CPCs  
 
Utilizing direct genetic labeling strategies, based on the putative stem cell markers 
aforementioned (e.g. c-Kit and Sca-1), helped to clarify whether these markers only 
label stem or progenitor cells in the heart. Furthermore, it provided insight on 
cardiomyogenic potential of these endogenous CPCs through lineage tracing studies. 
1.5.1 c-Kit CPCs 
During embryogenesis in mice, c-Kit+ cells appear as early as at embryonic day (E) 
6.5 in the cardiogenic mesoderm (Ferreira-Martins et al. 2012), endocardial cells at 
E8.5 and 9.5, and exhibit a broad distribution in the developing and adult heart 
including the inner layers of atrial and ventricular chambers with a preferential 
localization in the endothelium of vessels as well as subepicardium region (Bernex et 
Mesenchymal  
markers 




c-kit+ CD34-, CD45-,  
Lin- (Beltrami et al. 2003) 
c-kit+ Sca-1+ CD34+,  
CD45+ (Matsuura et al. 2004) 
Sca-1+ Flk-1-, CD31+ CD34-, CD45- (Oh et al. 2003) 
c-kit- Sca-1+ 
CD90+, CD105+,  
CD29+, CD44+,  
CD73+ 
CD31- CD34- (Tateishi et al. 2007) 
Sca-1+ PDGFRα+ CD90+, CD105+,  
CD29+, CD44+ Flk-1-, CD31- CD45- (Chong et al. 2011) 
c-kit- Sca-1+ CD29+ CD31- CD34-, CD45- (Takamiya et al. 2011) 
c-kit- Sca-1+ PDGFRα+ CD90-, CD105+,  
CD29+, CD44+ Flk-1-, CD31- CD34-, CD45- (Freire et al. 2014) 
c-kit- Sca-1+ CD44- CD31-, Tie2+ CD34-, CD45- (Pfister et al. 2005) 
c-kit+ Sca-1+ CD29+, CD44+ Flk-1+ CD34+, CD45- (Tomita et al. 2005) 
c-kit+ Sca-1+ CD31- CD34+,  
CD45+ (Martin et al. 2004) 
Epicardial  
progenitors c-kit- Sca-1+ Flk-1-, CD31- (Smart et al. 2011) 
c-kit+ Sca-1+ CD29+ Flk-1+, CD31+ CD34+ (Messina et al. 2004) 
c-kit- Sca-1+ Flk-1-, CD31- CD34-, CD45-,  
CD133- (Ye et al. 2012) 
Stem cell markers               
(c-kit/Sca-1/PDGFRα) 
Surface marker  
selected CPCs 







al. 1996, Limana et al. 2007, Sultana et al. 2015, van Berlo et al. 2014). Pulse-chase 
labeling of c-Kit+ cells during embryonic development in a tamoxifen inducible 
MerCreMer mouse model demonstrated the contribution of c-Kit+ cells to the different 
compartments of the adult heart (Figure 5) (Sultana et al. 2015, van Berlo et al. 
2014). In contrast to other studies, suggesting the existence of c-Kit as CPCs in the 
myocardial interstitium (Bearzi et al. 2007, Beltrami et al. 2003, Urbanek et al. 2003), 
evidence for a broad distribution of c-Kit+ cells was demonstrated (Figure 5B).  
 
 
Figure 5. c-Kit cell progeny in the adult heart. A Lineage tracing of c-Kit
+
 cells in the developing 
heart in transgenic MerCreMer mice. B Spatial distribution of c-Kit
+
 cells in the adult heart. EPDC: 
Epicardium-derived progenitor cells. 
 
Embryonic c-Kit+ cells appeared to have contributed mainly to blood vessel 
associated endothelial cells in the adult heart (~80% of c-Kit+ cells co-labeled with 
CD31+) with rare differentiation into cardiomyocytes (<0.1% of total cardiomyocytes) 
(Sultana et al. 2015, van Berlo et al. 2014). This limited cardiomyogenic potential of 
c-Kit+ CPCs was also supported in the aging heart and under pathological conditions 
using the same transgenic mouse model and postnatal reporter activation (Sultana et 





A 3-fold increase in cardiomyogenic activity of c-Kit+ CPCs was reported after 
infarction; however, the amount of newly generated cardiomyocytes by c-Kit+ CPCs 
remained too low for a palpable endogenous cardioregenative response (van Berlo et 
al. 2014). Conversely, Ellison et al. proposed that c-Kit+ CPCs are indispensable for 
cardiac regeneration (Ellison et al. 2013). Using lentiviral labeling of endogenous c-
Kit+ CPCs, they demonstrated that 10% of the newly formed myocytes in the injury 
site after myocardial infarction stemmed from c-Kit+ CPCs. These CPC-derived 
cardiomyocytes appeared functional and contained sarcomeric structures, but in 
immature state (Ellison et al. 2013). 
1.5.2 Sca-1 CPCs 
Sca-1+ CPCs were first identified by Matsuura et al. reporting that Sca-1+ cells 
isolated from the adult mouse heart were able to differentiate into beating 
cardiomyocytes in vitro (Matsuura et al. 2004). Moreover, Sca-1+ CPCs had the 
ability to differentiate into adipocytes and osteocytes, showing MSC-like 
characteristics. Although a human Sca-1 epitope has not been identified so far, 
antibody selection for mouse Sca-1 was applied successfully to isolate Sca-1+-like 
progenitors from the human heart (Smits et al. 2009). Recent studies in the mouse 
demonstrated that the majority of Sca-1+ cells in the heart were endothelial cells 
(>70%) and included a small fraction of smooth muscle cells (<5%) (Uchida et al. 
2013). Additional Sca-1+ cells in the myocardial interstitium were most likely 
comprised of cardiac fibroblasts (Furtado et al. 2014) and Sca-1+ progenitors closely 
associated with the cardiomyocyte basal lamina, expressing stem cell surface 
markers: c-Kit, CD34 and Abcg2 (ATP-binding cassette, sub-family G, member 2) 
(Uchida et al. 2013). In other studies, Sca-1+ CPCs that share some of the 
stem/progenitor cell markers (c-Kit, CD34) have been found in epicardial progenitor 
cells in the adult epicardium (Limana et al. 2007). In addition, Sca-1+ CPCs have 
been found to express the epicardium-derived progenitor cell marker, PDGFRα 
(Chong et al. 2011). Together, these findings suggest a epicardial origin of Sca-1+ 
cells. 
Given the specificity of PDGFRα as a marker for epicardial progenitors (Chong et al. 




cardiovascular compartment and stromal cells in the developing heart, Sca-
1+/PDGFRα+ CPCs were suggested to have the potential to differentiate into 
interstitial and smooth muscle cells, but not endothelial cells (Chong et al. 2011). This 
finding was contrary to recent findings, where most of the Sca-1+ CPCs were shown 
to differentiate into endothelial cells during physiological development (Uchida et al. 
2013). This contradiction regarding the differentiation potential of Sca-1+ cells might 
be explained either with the existence of two subtypes of Sca-1+ progenitors (Sca-
1+/PDGFR+ and Sca-1+/PDGFR-), as demonstrated in the aorta (Cho et al. 2013), 
giving rise to different cell types in the heart or the heterogeneity of Sca-1+ cells, 
composed of mainly endothelial cells which could mask the fate tracking of actual of 
Sca-1+ progenitors in the heart (Uchida et al. 2013). Nevertheless, with respect to 
cardiomyogenic potential of Sca-1+ CPCs, lineage tracing of Sca-1+ cells 
continuously labeled from embryonic stage to postnatal development revealed that 
Sca-1+ cells were able to contribute to cardiomyocyte renewal continuously under 
normal aging, but in a very low amount suggesting for their limited cardiomyogenic 
potential. Furthermore, they did not actively contribute to new cardiomyocyte 
formation even after injury (Uchida et al. 2013). 
1.5.3 Vessel resident progenitor cells  
So far, different types of blood vessel associated progenitors were identified based 
on their localization and specific marker expression, such as pericytes, mature vessel 
medial and adventitial progenitor cells (Kovacic and Boehm 2009). Pericytes have 
been discussed as mesenchymal stem cell (MSC)-like cells in the heart (Figure 6), 
with similar surface marker expression profile (e.g. Sca-1), the ability to undergo tri-
lineage differentiation into osteoblasts, chondrocytes, and adipoyctes (Crisan et al. 






Figure 6. Unique and shared properties of pericytes and mesenchymal stem cells. Schematic 
adapted from Wong et al. (2015). 
Pericytes have been recently defined as progenitors for smooth muscle cells, arising 
from epicardium during embryonic heart development. In addition, pericytes that are 
clonally related to smooth muscle cell are able to remain around the coronary arteries 
or tunica adventitia as cardiac progenitors, if they do not develop into smooth muscle 
cell (Volz et al. 2015). Consistent with this, the possibility that there are progenitor 
cells localizing in the tunica media or adventitia of mature vessels was suggested by 
several studies. Progenitor cells expressing stem cell markers including c-Kit, Sca-1, 
CD34 and residing in the tunica adventitia with the potential to differentiate into 
smooth muscle cells were recently identified (Hu et al. 2004). Another study reported 
that there are also progenitor cells, so called side population cells located in the 
tunica media that express Sca-1 and CD34, being capable of giving rise to smooth 
muscle and endothelial cells (Sainz et al. 2006). In addition to pericytes and 
adventitial cells, Kramann et al. reported another type of perivascular progenitors 
residing in pericyte niche (Kramann et al. 2015), GLI family zinc finger 1 (Gli1) + cells 
around the vasculature in close proximity to pericytes. These pericyte niche-
associated cells do not show pericyte-specific markers such as CD146 and NG2 
(CSPG4; chondroitin sulfate proteoglycan 4). Additionally, these cells display MSC 
properties and markers including Sca-1 and PDGFRα, suggesting a epicardium-
derived progenitors origin (Smith et al. 2011). Given the fact that virtually all the 
organs contain MSCs with subendothelial localization, it is likely that vasculature in 




(Kovacic and Boehm 2009, Wong et al. 2015). However, due to the limited 
understanding on the origin of cardiac progenitor cells and the heterogeneous 
expression profile of stem cell surface markers (e.g. c-Kit and Sca-1) in the heart, it is 
still not clear if these progenitors simply originate from the vasculature or are 
descendants of a common stem cell source (e.g. epicardium) or remnants of 
cardiovascular progenitors from embryonic development (Valente et al. 2014). The 
spatial distribution of putative cardiac stem/progenitor cells in the heart is 
schematically displayed in Figure 7; the relationship between these progenitors still 
remains to be defined. 
 
Figure 7. Schematic overview of the spatial distribution of putative CPCs. 
 
1.6 Exogenous regeneration by CPCs 
Endogenous cardiac repair by resident CPCs is limited in the adult heart. Thus, 
implantation of CPCs into the myocardium or their pharmacological activation has 
been proposed as therapeutic strategies in heart disease (Beltrami et al. 2003). 
Accordingly, small and large animal models (e.g. rat and pig) were utilized to assess 
the cardio-regenerative potential of c-Kit+ CPCs and also to develop strategies to 
enhance their retention rate upon delivery into the myocardium. In vitro expanded 
and growth factor (e.g. HGF and IGF-1) stimulated c-Kit+ CPCs displayed robust 




vascularized myocardium, attenuating left ventricular dysfunction after myocardial 
infarction (Tillmanns et al. 2008). Similarly, autologous c-Kit+ CPC implants induced 
functional myocardial tissue regeneration within chronically scarred myocardium in 
rat and pig heart (Bolli et al. 2013, Rota et al. 2008, Tang et al. 2010).  
Although the potential mechanisms underlying the cardio-supportive effects of c-Kit+ 
CPCs still needs to be defined, it is unlikely that differentiation of transplanted CPCs 
can explain the observed improvements. Instead, paracrine mediated effects initiating 
endogenous repair through recruitment of endogenous CPCs are discussed as 
alternative mechanism. Collectively, available animal studies provided convincing 
evidence for feasibility and safety of c-Kit+ CPC implantation with additional hints for 
efficacy (van der Spoel et al. 2011). 
1.7 Cardiac stem cell based therapy 
Various cell types from different sources have been tested experimentally and 
clinically for their capacity to regenerate the heart using different routes of 
administration into the myocardium. Cell sources used in direct intracoronary or 
intramyocardial transplantations include; autologous bone marrow (BM)-derived cells 
(unselected BM-derived mononuclear and –mesencyhmal stem cells) (Bartunek et al. 
2013, Lunde et al. 2006, Meyer et al. 2009, Mushtaq et al. 2014, Perin et al. 2012, 
Roncalli et al. 2011), skeletal muscle progenitors (satellite cells) (Menasche et al. 
2008), peripheral blood cells (Assmus et al. 2007), adipose tissue-derived MSCs 
(Houtgraaf et al. 2012), heart-derived stem/progenitor cells (c-Kit+ and cardiosphere 
progenitors) (Bolli et al. 2011, Chugh et al. 2012, Makkar et al. 2012). Besides direct 
intramyocardial delivery of exogenous cells, mobilization of endogenous progenitors 
from bone marrow by systemic administration of defined cytokines (e.g. erytropoieitn 
[EPO] and granulocyte-colony stimulating factor [G-CSF]) were also evaluated as 
alternative strategies (Achilli et al. 2010, Taniguchi et al. 2010). Candidate cell 
populations to induce myocardial regeneration and their delivery routes to the heart 















Figure 8. Clinically tested cell sources for heart regeneration. Schematic adapted from Doppler et 
al. (2013). 
Being easy to harvest and apparently immune privileged, BM-derived stem/progenitor 
cells have been considered feasible and safe to be applied in clinical therapies 
without adverse effects so far, although it is also speculated that MSCs can transform 
into malignant tumors (Miura et al. 2006, Rubio et al. 2005). Unselected BM-derived 
mononuclear cells containing a mixture of endothelial progenitors, angioblasts and 
hematopoietic stem cells were thought to be an ideal cell source to induce 
neovascularization and new cardiomyocyte formation (Pavo et al. 2014). These cells, 
however, displayed a low abundance of relevant progenitors, modest clinical results 
and lack of convincing evidence for hematopoietic stem cells to differentiate into 
cardiomyocytes. Hence, the mode of action remains, despite the in some studies 
clinically observed beneficial effects and a suggested paracrine activity, elusive 
(Suzuki 2015). 
The discovery of the heart containing endogenous cardiac progenitors with the 
capability to differentiate into vascular cells and cardiomyocytes initiated the isolation 
and in vitro expansion of these cells to be tested in several Phase IIa/b human 
clinical trials. These include the (1) cardiosphere-derived autologous stem cells to 




cells in patients with ischemic cardiomyopathy (SCIPIO; (Bolli et al. 2011)) and (3) 
autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy 
(ALCADIA; (Takehara et al. 2012)) trials. In addition, another clinical trial, so called 
safety and efficacy evaluation of intracoronary infusion of allogeneic human cardiac 
stem cells in patients with acute myocardial infarction (CARE-MI) is ongoing in Phase 
I and II under the sponsorship of Coretherapix company, Spain (CARE-MI trial; 
Clinical Trial Identifier: NCT02439398). 
In the CADUCEUS trial, patients were treated with 25 million autologous 
cardiosphere-derived progenitor cells (CDCs) isolated from right ventricular 
endomyocardial biopsies and injected through intracoronary infusion into the infarct 
related artery 1.5-3 months after myocardial infarction. The hypothesis was that scar 
tissue would be converted into viable myocardium (Makkar et al. 2012). Injection of 
CDCs significantly reduced the infarct size, increased the amount of viable 
myocardium as well as thickness in the peri-infarct zone at 6-12 months follow up, 
although there was no difference detected in left ventricular (LV) ejection fraction 
(Makkar et al. 2012). The SCIPIO trial was performed in patients with heart failure 
due to ischemic cardiomyopathy injecting 0.5-1 million of autologous c-Kit+ CPCs 
derived from the atrial appendage. A reduction in infarct size and improvement in 
ejection fraction were reported after one and four year follow-up (Bolli et al. 2011). 
The ongoing ALCADIA trial differs from these previous studies in that stem cell 
delivery is combined with a biodegradable gelatin hydrogel scaffold for sustained 
FGF-2 release and enhanced cell retention (ALCADIA trial; Clinical Trial Identifier: 
NCT00981006). Taken together, these first clinical trials revealed that autologous 
transplantation of CPCs is feasible and safe.  
More recently and as a consequence of the failure of autografts to form new 
cardiomyocytes there is a paradigm shift from autologous to allogenic implantations 
(CARE-MI trial; Clinical Trial Identifier: NCT02439398). Lauden et al. showed that 
allogeneic c-Kit-selected human CPCs (hCPCs) might exhibit a beneficial 
immunomodulatory effect. hCPCs express programmed death ligand 1 (PD-L1) 
protein which plays an important role in immunesuppression via acting as an 
inhibitory signal on the proliferation and activation of CD8+ T-cells and activating 




altered upon treatment with interferon gamma (IFN-γ), which is a pro-inflammatory 
cytokine secreted during myocardial infarction and infarct remodelling. This 
phenotype of hCPCs and the possibility for cryopreservation suggest that cell banks 
with allogeneic c-Kit-selected hCPCs may find an application in patients with acute 
myocardial infarction (Lauden et al. 2013).  
Although there is first evidence of clinical efficacy, the main mechanisms for these 
cardio-supportive effects of transplanted c-Kit+ CPCs are not yet fully understood. 
There are, however, several mechanisms proposed for these beneficial effects 
(Lauden et al. 2013), that can be summarized as direct and indirect effects of 
exogenously transplanted CPCs on the maintenance of heart structure and function. 
CPCs delivered into the infarcted myocardium may directly contribute to 
cardiomyogeneis and angiogenesis either via paracrine signaling (e.g. growth factors 
and cytokines) enhancing proliferation and survival of endogenous cardiomyocytes 
and vascular cells or giving rise to new cardiomyocytes and vascular cells (smooth 
muscle cells and endothelial cells). Besides this direct effect of CPCs on cardiac 
regeneration, they may also indirectly mediate cardio-supporting activity through 
regulating heart injury responses (e.g. reduced inflammation, fibrosis and 
remodeling) and activating endogenous CPCs to differentiate into cardiac cells. All 












Figure 9. Schematic overview of potential mechanisms involved in heart repair upon CPC 
transplantation in vivo. Core panel (pink-colored): Direct contribution of CPCs to heart regeneration 
either by direct transdifferentiation or paracrine signaling. Outer panel (grey-colored): Indirect 
contribution of CPCs to heart regeneration and function through activating endogenous CPCs and 
regulating heart injury responses (e.g. reduced inflammation, fibrosis and remodeling).   
1.8 EHM as an in vitro cardiac muscle model 
Cardiac tissue engineering focuses on the development of biomimetic artificial 
cardiac muscle constructs. Engineered heart muscle (EHM) shows structural and 
physiological characteristics of native heart muscle, which renders it a high-fidelity in 
vitro platform to also study cell-cell interactions within a three-dimensional heart 
muscle context (Naito et al. 2006, Tiburcy et al. 2011, Zimmermann et al. 2002). 
Characteristic properties of EHM comprise: 1) the formation of a functional 
syncytium; 2) terminal differentiation of cardiomyocytes; 3) organotypic maturation 
with structural and functional properties of the postnatal heart (Christalla et al. 2012). 
Stromal cells play an essential role in this process by providing and maintaining a 
cardio-instructive extracellular matrix (ECM) milieu and paracrine support to guide 





1.9 Aims of the study 
A better understanding of the biological activity of CPCs may help to refine 
therapeutic strategies aiming at the regeneration of the failing heart. We 
hypothesized that EHM could be used as an in vitro heart surrogate platform to 
scrutinize and define the cardio-supportive effects of CPCs.  
This study tested the following specific hypotheses:  
1) CPCs support functional heart muscle formation in vitro. 
2) CPCs elicit cardioprotective effects upon hypoxic injury.  
The hypotheses were investigated in EHM from rat, mouse, and human cells as 
indicated. A new transgenic reporter model was established to study the role of 
hypoxia.  
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2 Materials and Methods 
 
2.1 Preparation of cardiomyocytes 
Cardiomyocytes were harvested from neonatal rat heart (section 2.1.1) as well as 
mouse (section 2.1.2) and human (section 2.1.3) embryonic stem cells. Organ 
harvest was approved by the responsible animal protection authorities (LAVES - AZ: 
10.13/10.14). The use of human embryonic stem cells was approved by the Robert-
Koch-Institute (AZ: 1710-79-1-4-16) according to §6 Stammzellgesetz (StZG).  
2.1.1 Neonatal rat cardiomyocytes 
Neonatal rat hearts (day 0-3) were dissociated by using a digestion protocol based 
on trypsin/DNAse I (Zimmermann et al. 2000). Cells were thereafter pre-plated for 1 
hour at 37 °C, 5% CO2 on plasma treated cell culture dishes. The non-attached cell 
suspensions were harvested as myocyte fraction and designated as neonatal rat 
cardiomyocytes (NRCMs). The purity of cardiomyocytes was determined by flow 
cytometry (BD LSR II; BD Biosciences) of cells stained for α-sarcomeric actinin 
(Sigma-Aldrich, see Appendix A3 for antibody dilution and section 2.6.2 for 
immunostaining protocol). 
2.1.2 Mouse embryonic stem cell-derived cardiomyocytes 
Upon mating of transgenic ROSA26 ODD-Luc/+ (heterozygous for ODD-Luc knock-in 
in the ROSA26 locus; see Appendix A4 for detailed background of the mice strain), 
zygotes at blastocyst stage were harvested and cultured on inactivated mouse 
embryonic fibroblasts (mEFs). Inner cell mass outgrowths from blastocysts were 
isolated and cultured on mEFs to give rise to ODD-Luc mouse embryonic stem cell 
(mESC) colonies. Subsequently, ODD-Luc mESCs were electroporated with a DNA 
construct expressing a neomycin resistance gene (neoR) under the transcriptional 
control of cardiomyocyte restricted alpha-myosin heavy chain (αMHC) promoter and 
a hygromycin resistance gene (hygroR) under ubiquitiously active phosphoglycerate 
(PGK) promoter (Klug et al. 1996) and selected under hygromycin (500 µg/ml for 7 
days). The establishment of bitransgenic ODD-Luc x αMHC-neoR mESC line was 
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performed by Andreas Schraut (Institute of Pharmacology and Toxicology, University 
Medical Center Göttingen). ODD-Luc x αMHC-neoR mESCs were expanded on 
feeder layers composed of mitotically arrested MEFs (γ-irradiated with 30 Gy in 
Biobeam 8000, STS GmbH) cultivated in mESC culture medium (Appendix A1). 
Cardiac differentiation was performed in 100 ml spinner flask cultures (0.1 x 106/ml 
seeding density) for 11 days, followed by additional 7 days of cardiomyocyte 
selection with G418 (400 µg/ml) in mESC differentiation medium (Appendix A1) as 
shown in Figure 10. Spontaneously beating cardiac bodies (CBs) were dissociated 
with a digestion protocol based on collagenase type I solution (Appendix A1) and 
trypsin-EDTA (0.25%). The purity of cardiomyocytes was detected by flow cytometry 
analysis of sarcomeric α-actinin staining (see Appendix A3 for antibody dilution and 
section 2.6.2 for immunostaining protocol). Cardiomyocyte yield per input mESCs 
was in the range between 1:1 and 1:2 after spontaneous differentiation and selection. 
Purity of cardiomyocytes is represented as a result in section 3.2.1. 
 
Figure 10. Cardiac differentiation of mESCs. Schematic representation of mouse cardiac 
differentiation: suspension culture of mESCs cultivated in spinner flasks for 11 days to induce 
spontaneous cardiac differentiation, followed by 7 days of selection of spontaneously beating cardiac 
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2.1.3 Human embryonic stem cell-derived cardiomyocytes 
The human embryonic stem cell line “HES2” (Embryonic Stem Cell International, 
Singapore), genetically modified to stably and ubiquitously express a tandem dimer 
red fluoresence protein (tdRFP) from the ROSA26 locus (finally designated 
hES2.R26) was kindly provided by Gordon Keller (Irion et al. 2007). hES2-RFP cells 
were maintained and differentiated under serum free conditios (Hudson et al. 2012) 
with minor modifications. Briefly, hESCs were initially cultured on irradiated hFFs in 
hESC culture medium (Appendix A1) and passaged using EDTA digestion solution 
(0.5 mol/L, pH 8, AppliChem) for expansion and single cell adaptation. Thereafter, 
hES2.R26 cells were plated on feeder free, Matrigel™ (Corning, 1:30 diluted in 1x 
PBS)-coated flasks in hESC-conditioned medium (Appendix A1) with every day 
medium change. Upon plating of hESCs on Matrigel-coated plates with a seeding 
density of 5 x 104-1 x 105 cells/cm² in hESC-conditioned medium for one day, hESCs 
were rinsed with hCM medium (Appendix A1) and cultured in mesoderm-induction 
medium (Appendix A1) for 3 days. After another washing step with hCM medium, 
cells were cultured in cardiac specification medium (Appendix A1) for the following 10 
days. After two weeks of differentiation, cardiomyocytes were metabolically selected 
(Tohyama et al. 2013) in hCM selection medium (Appendix A1) for 5 days to obtain a 
highly enriched cardiomyocyte population. 
Following the purification step, cardiomyocytes were washed two times with 1x PBS 
at room temperature (RoT) and subsequently, incubated in hCM digestion solution 
(Appendix A1) for 4 minutes at RoT and 10 minutes at 37 °C for digestion. Harvested 
cardiomyocytes were either seeded on cell culture flasks pre-coated with Matrigel™ 
(Corning, 1:30 diluted in 1x PBS) or directly used to generate human engineered 
heart muscle (hEHM). The purity of cardiomyocytes was detected by flow cytometry 
analysis of sarcomeric α-actinin staining (see Appendix A3 for antibody dilution and 
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2.2 Preparation of non-myocytes 
 
Cardiac progenitor cells (CPCs) from mouse (mCPC; section 2.2.1) and human 
(hCPC; section 2.2.2) heart were used. Fibroblasts were isolated from mouse 
embryos (MEF; section 2.2.3) and human foreskin (hFF; section 2.2.4). Human 
cardac fibroblasts (hCF) were acquired from Lonza.  
2.2.1 Mouse CPCs 
We used two different types of murine cardiac progenitor cells (mCPCs); Sca-1-
CPCs and c-Kit-CPCs isolated from adult mouse heart. GFP-labeled Sca-1-mCPCs 
overexpressing micro RNA 133a (miR-133a-CPCs) and micro RNA control (miR-
control-CPCs) were kindly provided by Antonio Bernad (Izarra et al. 2014). GFP-
labeled c-Kit-mCPCs (GFP+ mCPCs) were kindly provided by Mark Sussman 
(Fischer et al. 2009). CPCs were maintained in mCPC medium (Appendix A1) under 
21% O2 and passaged with 0.05% Trypsin-EDTA (phenol red, #25300-054, Gibco) at 
80% confluency. 
2.2.2 Human CPCs 
Human CPCs (hCPCs) isolated based on the c-Kit surface protein from right atrial 
appendages of patients were kindly provided by Coretherapix Biomedicine, Spain 
(Lauden et al. 2013). hCPCs (wild type or GFP-labeled; see Appendix A4) were 
delivered in frozen aliquots and directly used after thawing to generate hEHM without 
being cultured in our laboratory. 
2.2.3 Mouse embryonic fibroblasts 
Mouse embryonic fibroblasts (mEFs) were harvested at days post coitum (d.p.c) 
12.5-13.5 by Andreas Schraut. mEFs were maintained in mEF medium (Appendix 
A1). For passaging, mEFs were enzymatically digested with 0.25% Trypsin-EDTA 
(#25200056, Gibco) at 80% confluency and split at a 1:3 ratio for further expansion. 
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2.2.4 Human foreskin fibroblasts 
Human foreskin fibroblasts (hFFs) were purchased from the American Type Culture 
Collection (ATCC). hFFs were passaged with TrypLE (Tryple™ Express Enzyme 1X, 
no phenol red, #12604-013, Gibco) and cultured in hFF medium (Appendix A1). hFFs 
were lentivirally transduced to generate a stable cell line expressing GFP. Lentiviral 
particles were generated by co-transfecting pGIPZ with pMD26 and pSPAX2 helper 
plasmids into human embryonic kidney (Sagoo et al.) 293-T cells using the FuGENE 
HD transfection protocol (Promega). After a medium change, virus-containing 
medium was harvested every 24 hours for 72 hours. Viral particles were pooled and 
concentrated by centrifugation using Amicon® Ultra Centrifugal Filters (Millipore). 
Concentrated virus was stored at -80 °C. To transduce hFFs, cells were treated with 
polybrene (10 μg/ml) in culture medium containing 0.5% fetal bovine serum (FBS; 
#10270, Gibco) at 37 °C for 10 minutes. Thereafter, virus containing medium was 
added drop wise on top of the cells and incubated at 5% CO2, 37 °C for 24 hours. 
Finally, the medium was exchanged with fresh hFF medium and transduced hFFs 
were selected with 1 µg/ml puromycin for 5 days. 
2.3 EHM 
Engineered heart muscle (EHM) was generated from neonatal rat heart and mouse 
or human embryonic stem cell-derived cardiomyocytes with CPCs or fibroblasts as 
indicated below.  
2.3.1 Rat EHM 
NRCMs were mixed with adult mouse heart-derived miR-control CPCs or miR-133a-
CPCs in a 70/30% ratio (2.5 x 106 cell/EHM) and mixed with a master mix containing 
collagen type I from rat tail according to the amounts mentioned in Table 2. Rat 
EHMs (rEHMs) were made as previously described (Godier-Furnemont et al. 2015, 
Zimmermann et al. 2000). Briefly, the rEHM reconstitution mixture was cast into 
circular molds (inner/outer diameter: 8/16 mm) (Naito et al. 2006) and supplemented 
with rEHM medium (Appendix A1) following incubation for 1 hour at 37 °C. rEHMs 
were allowed to condense for 7 days in the casting mold. Subsequently, rEHMs were 
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transferred and maintained on phasic stretchers from culture day 7 to day 12 to 
induce functional maturation under mechanical loading (Figure 11). 
Number of rEHMs 4x rEHMs 
  Volume (µl) 
Rat collagen (3.4 mg/ml) 940 
2x rEHM DMEM (Appendix A1) 940 
0.1 N NaOH 182 
Matrigel™ 400 
Cell suspension (2.75 x 106/EHM) 1738 
Total volume 4200 
 
900 µl/EHM 
    Table 2. rEHM master mix. 
 
 
Figure 11. Construction of rat EHM. A Rat EHMs were maintained in casting molds for consolidation 
for 7 days. B Rat EHMs were exposed to mechanical loading on phasic stretchers at 1 Hz for 24 hours 
and 2 Hz for the following 4 days until force measurement (Zimmermann et al. 2002). C Measurement 
of force of contraction (FOC) under isometric conditions in a thermostatted organ bath (37 °C) filled 
with Tyrode’s solution (Appendix A1).   
2.3.2 Mouse EHM 
mESC-derived cardiomyocytes (mCMs) were mixed with GFP+ mCPCs or mEFs in a 
70/30% ratio to generate mouse EHM (mEHM). Co-cultured cells were subsequently 
mixed with a master mix containing collagen type I isolated from rat tail (Table 3). 
Briefly, the mEHM cell mixture was cast in circular molds with an inner/outer diameter 
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of 2/4 mm (Tiburcy et al. 2014) as shown in Figure 13 and supplemented with mEHM 
medium (Appendix A1) following incubation for 1 hour at 37 °C. On culture day 3, 
mEHMs were transferred onto static stretchers where they were exposed to 
mechanical loading for an additional 11 days. 
Number of mEHMs 4x mEHMs 
  Volume (µl) 
Rat collagen (4.2 mg/ml) 399 
2x mEHM DMEM (Appendix A1) 399 
0.1 N NaOH 78.5 
Cell suspension (1.5 x 106/EHM) 1223.5 
Total volume 2100 
 
450 µl/EHM 








Figure 12. Casting mold for mouse and human EHM. Teflon disc (i) with 11 mm diameter, 5 mm 
height) was used as a spacer upon addition of silicone. Removal of the Teflon discs after hardening of 
the silicone established circular recesses (Tohyama et al. 2013). Silicone tubing (iii) with inner/outer 
diameter of 2/4 mm (Tiburcy et al. 2014) was placed on a central silicone core (Tohyama et al. 2013) 
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2.3.3 Human EHM 
Human engineered heart muscle (hEHM) was generated by mixing RFP+ hCMs with 
GFP+ hCPCs or GFP+ hFFs in 70/30% ratio in a master mix containing bovine 
collagen type I (Table 4). 
Number of hEHMs 4x hEHMs 
  Volume (µl) 
Bovine collagen (6.9 mg/ml) 271 
2x hEHM RPMI (Appendix A1) 271 
0.1 N NaOH 53 
Cell suspension (1.45 x 106/EHM) 1511 
Total volume 2106 
 
450 µl/EHM 
    Table 4. hEHM master mix. 
hEHM mixture was cast into circular molds (Figure 12) with an inner/outer diameter 
of 2/4 mm and supplemented with serum-free hEHM medium (Appendix A1) following 
an incubation for 1 hour at 37 °C. On culture day 3, hEHMs were transferred onto 
static or dynamic stretchers to be exposed to mechanical loading. After culture day 
14 or 28, hEHMs were subjected to isometric force measurements. 
2.4 Isometric force measurement 
EHM functionality was assessed by isometric force measurement in thermostatted 
organ baths (37 °C; Figure 11C) perfused with carbogen (95% O2, 5% CO2) to 
stabilize the pH at 7.4 as described previously (Zimmermann et al. 2000). EHMs 
were exposed to electrical stimulation (mEHM and rEHM: 2 Hz, hEHM: 1.5 Hz, 200 
mA) to contract in Tyrode’s solution (Appendix A1). EHMs were firstly preloaded to 
the maximum length where they generated the maximum force (Lmax according to 
the Frank-Starling mechanism). EHMs kept at Lmax were exposed to cumulatively 
increasing calcium concentrations (0.2 mM to 4 mM) to document maximal inotropic 
capacity and calcium sensitivity. Subsequently, EHMs were exposed to 1 µmol/L 
isoprenaline and 10 µmol/L carbachol (both from Sigma-Aldrich) at EC50 calcium 
concentrations. Force of contraction (FOC) data was acquired by BMON 32 and 
analyzed by AMON 32 software (Föhr Medical Instruments).  
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2.5 Immunostaining and microscopy 
EHMs were fixed with 4% formaldehyde (FA) overnight at 4 °C followed by washes in 
PBS. From this step on, EHM pieces were either directly proceeded to whole mount 
staining or the complete EHM rings were embedded in 4% agarose for subsequent 
vibratome sectioning (Leica vibratome). EHM pieces or sections with 100 µm of 
thickness were blocked in permeabilizing blocking buffer (Appendix A1) overnight at 
4 °C. Next, EHMs were treated with primary antibodies (see Appendix A3 for 
antibody dilutions) in the blocking buffer overnight at 4 °C. Primary antibodies were 
extensively washed; two times with PBS and one time with blocking buffer. 
Thereafter, EHMs were incubated in blocking buffer with suitable secondary 
antibodies (see Appendix A3 for antibody dilutions) and Hoechst (10 µg/ml, BD 
Biosciences, see Appendix A3 for the dilution) for DNA staining overnight at 4 °C. 
Following the washing steps; two times with PBS, one time with permeabilizing 
blocking buffer and one time with PBS, EHMs were mounted on microscope slides 
and proceeded to confocal microscopy imaging (Zeiss LSM 710).    
2.6 Flow cytometry 
For single cell analyses by flow cytometry EHM had to be dispersed enzymatically 
and exposed to specific antibody and DNA labeling. 
2.6.1 Dissociation of EHM 
EHMs were incubated in 1 ml of collagenase solution (Appendix A1) for 1 hour at 37 
 C. The supernatant was collected and the remaining EHM fragments were again 
exposed to 1 ml of fresh hCM digestion solution (Appendix A1) for 30 minutes at 37 
 C to achieve a complete dissociation. Supernatant volume was recorded and 
subjected to automated cell counting by an electric current exclusion assay (CASY 
model TTC; Roche) to measure cell number and viability. Thereafter, cells were 
passed through a 70 µm cell strainer to remove clumps and either directly proceeded 
to flow cytometry for live analysis or fixed with ice-cold 70% ethanol or 4% FA at RoT 
for immunofluorescence staining. 
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2.6.2 Immunostaining for intracellular antigens 
Cells digested from EHM were labeled with primary antibodies directed against 
sarcomeric α-actinin (see Appendix A3 for the antibody dilution) to determine the 
myocyte amount out of total cell population within the EHM. Firstly, ethanol was 
removed by a centrifugation step (300 x g, 5 minutes) and subsequently cells were 
permeabilized in permabilizing blocking buffer (Appendix A1) for 10 minutes on ice. 
Next, cells were incubated with the primary antibody for 45 minutes on ice. 
Subsequent to washing steps; one time with PBS and one time with the blocking 
buffer, cells were incubated with a suitable secondary antibody (see Appendix A3) 
together with Hoechst DNA-binding dye (10 µg/ml, BD Biosciences, see Appendix A3 
for the dilution) for 30 minutes in the dark at RoT. Following the washing steps; one 
time with PBS and one time with the blocking buffer, cells were suspended in 500 µl 
of PBS and subjected to flow cytometry analysis. 
2.6.3 Immunostaining for cell surface proteins 
CPCs and fibroblasts were stained with the corresponding antibodies against cell 
surface antigens; progenitor/stem cell markers (c-Kit, Sca-1), endothelial cell marker 
(PECAM1 [CD31]), mesenchymal cell markers (CD90, CD105, PDGFRA), and the 
common leukocyte marker (CD45). CPCs and fibroblasts were used directly from 
frozen aliquots. Cells were thawed in culture medium and subsequently washed with 
PBS. Next, CPCs and fibroblasts were exposed to the indicated antibodies (see 
Appendix A3 for the antibody dilution) in PBS with 5% FBS for 15 minutes at 4 °C in 
the dark. After an additional washing step with 3 ml of PBS, cells were subjected to 
flow cytometry (BD LSR II; BD Biosciences). 
2.6.4 Sorting of EHM-derived cells 
Cell mixtures composed of RFP+ cardiomyocytes and GFP+ non-myocytes (hFFs and 
hCPCs) obtained from EHM digestion were proceeded to fluorescence-activated cell 
sorting (FACS) based on their fluorescence labeling. EHM cells were stained with 
Sytox red dead cell stain (# S34859, Molecular Probes) and Hoechst DNA-binding 
dye (10 µg/ml, BD Biosciences, see Appendix A3 for the dilution) to exclude dead 
cells and cell clusters, respectively, during flow cytometry analysis. RFP+ myocytes 
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and GFP+ non-myocytes were recorded within the population gated for live (Sytox 
negative) and single cells were subsequently sorted (FACSAria II; BD Biosciences) 
into separate 15 ml polypropylene tubes containing Trizol (Invitrogen) for RNA 
isolation. 
2.7 Gene expression analysis 
Gene expression analysis was done by semi-quantitative PCR (PCR), quantitative 
PCR (qPCR) and RNA-sequencing (RNAseq). 
2.7.1 RNA isolation 
Total RNA was isolated using Trizol reagent according to manufacturer’s instructions. 
The amount and purity of RNA (to assess DNA and phenol contaminations 
respectively; OD260/OD280: ~2.0, OD260/OD230: 2.0-2.2) were identified by the 
Nanodrop spectrophotometer (Thermo Scientific).  
 
Gene expression analysis in rEHMs was performed by Alberto Izarra (Spanish 
National Center for Cardiovascular Research - CNIC). rEHM samples were shipped 
to CNIC on dry ice for RNA isolation followed by PCR for insulin-like growth factor 1 
(IGF-1), fibroblast growth factor 2 (bFGF), vascular endothelial growth factor A 
(VEGF-A) and hepatocyte growth factor (HGF) with mouse specific primers to only 
amplify transcripts encoding the respective growth factors in the mouse Sca-1-CPC 
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2.7.2 Reverse transcription 
RNA samples were treated with DNase I (#04716728001, Roche) according to the 
protocol described below (Table 5) to remove possible contaminating genomic DNA.  
  Volume 
RNA (1 µg) 8 µl 
DNase incubation buffer 1 µl 
DNase (10 U/µl) 0.2 µl 
   Table 5. Composition of DNase treatment. 
Dnase treatment reaction was performed at 37 °C for 20 minutes. Subsequently, 1 µl 
of EDTA solution (1:5 diluted from RNase free EDTA stock solution, 0.2 mol/L, pH 
8.0) was pipetted into the reaction mix to inhibit DNase activity and incubated at 75  
C for 10 minutes.   
cDNA synthesis was performed by using High Capacity cDNA Reverse Transcription 
kit according to the manufacturer’s instructions (Applied Biosystems). Briefly, 10 µl of 
Master mix for cDNA synthesis (Table 6) was mixed with 10 µl of RNA sample as 
described above and cDNA reverse transription reaction was run following the 
program summarized in Table 7. 
  Volume 
10x RT buffer 2 µl 
25x dNTPs (100 mM) 0.8 µl 
10x RT Random Oligo dT primers 2 µl 
RNase inhibitor  1 µl 
Diethylpyrocarbonate (DEPC) water 3.2 µl 
Multiscribe Reverse Transcriptase (50 U/µl) 1 µl 
  Table 6. Composition of cDNA synthesis reaction. 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 min 120 min 5 min − 
    Table 7. cDNA synthesis protocol.  
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2.7.3 Polymerase chain reaction 
Subsequent to cDNA synthesis, semi-quantitative PCR was performed with primers 
targeting transcripts from specific genes of interest (Appendix A2) using TaKaRa Ex 
Taq kit. Briefly, 50 ng of cDNA was mixed with a master mix containing 5’ and 3’ 
primers with either 100 nmol/L or 200 nmol/L final concentration as indicated in the 
tables below (Table 8 and 9) for each gene (IGF-1, FGF-2, VEGF-A, HGF, platelet 
derived growth factor [PDGF], v-kit hardy-zuckerman 4 feline sarcoma viral oncogene 
homolog [c-Kit], Nk2 homeobox 5 [NKX2-5], Gata binding protein 4 [GATA4], Actin, 
alpha, cardiac muscle 1 [ACTC1], Cardiac troponin I, type 3 [CTnI], PECAM1 [CD31] 
and Glyceraldehyde-3-Phosphate Dehydrogenase [GAPDH]). The PCR reactions 
were run on a Veriti® 96-Well Thermal Cycler (Applied Biosystems) as indicated 
below (Table 10-14). 
  Master Mix 
Number of samples 4x 
10x ExTaq Buffer 5 µl 
dNTP mix 4 µl 
ExTaq 0.25 µl 
5' primer (10 µmol/L) 1 µl (final con. 200 nmol/L) 
3' primer (10 µmol/L) 1 µl  (final con. 200 nmol/L) 
ddH2O 36.75 µl 
 
12 µl/sample 
cDNA sample 1 µl 
Total volume/sample 13 µl 
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  Master Mix 
Number of samples 4x 
10x ExTaq Buffer 5 µl 
dNTP mix 4 µl 
ExTaq 0.25 µl 
5' primer (10 µM) 0.5 µl (final con. 100 nM) 
3' primer (10 µM) 0.5 µl (final con. 100 nM) 
ddH2O 37.75 µl 
 
12 µl/sample 
cDNA sample 1 µl 
Total volume/sample 13 µl 
 
   Table 9. Composition of the PCR reaction for CD31.  
 
Cycle step Temperature Time Cycles 
Initial denaturation 95 °C 60 sec. 1x 
Denaturation 95 °C 15 sec. 
35x Annealing 60 °C 15 sec. 
Extension 72 °C 30 sec. 
Final extension 72 °C 300 sec. 1x 
 
   Table 10. PCR program for FGF-2/VEGF-A/PDGF/GAPDH. 
 
Cycle step Temperature Time Cycles 
Initial denaturation 95 °C 60 sec. 1x 
Denaturation 95 °C 15 sec. 
35x Annealing 60 °C 30 sec. 
Extension 72 °C 60 sec. 
Final extension 72 °C 300 sec. 1x 
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Cycle step Temperature Time Cycles 
Initial denaturation 95 °C 60 sec. 1x 
Denaturation 95 °C 30 sec. 
35x Annealing 56 °C 30 sec. 
Extension 72 °C 60 sec. 
Final extension 72 °C 300 sec. 1x 
 
    Table 12. PCR program for NKX2-5. 
 
Cycle step Temperature Time Cycles 
Initial denaturation 95 °C 60 sec. 1x 
Denaturation 95 °C 30 sec. 
30x Annealing 60 °C 30 sec. 
Extension 72 °C 60 sec. 
Final extension 72 °C 300 sec. 1x 
 
    Table 13. PCR program for CD31/c-Kit. 
 
Cycle step Temperature Time Cycles 
Initial denaturation 95 °C 60 sec. 1x 
Denaturation 95 °C 30 sec. 
35x Annealing 55 °C 30 sec. 
Extension 72 °C 60 sec. 
Final extension 72 °C 300 sec. 1x 
 
    Table 14. PCR program for HGF. 
 
2.7.4 Agarose gel electrophoresis 
Amplified DNA fragments by PCR were visualized by agarose gel electrophoresis for 
gene expression analysis. 2% agarose gels (ultra-pure agarose; AppliChem) were 
prepared in TAE buffer (Appendix A1). The agarose gel mixture was heated in a 
microwave until agarose particles were completely dissolved. Prior to gel 
polymerization ethidium bromide was added (final concentration 0.2 µg/ml) for 
visualization of the DNA under UV light. Agarose gels were poured into standard 
casting trays. Upon polymerization, agarose gels were loaded with the cDNA 
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samples mixed with DNA gel loading dye (#R0611, ThermoFisher Scientific) and a 
DNA ladder (Gene rulerTM 100 bp Plus DNA ladder, #SM0321, ThermoFisher 
Scientific). Elecrophoretic separation was at 90 V for 1-2 hours at RoT. 
2.7.5 Quantitative PCR 
To analyze the expression of cardiac genes in flow cytometry sorted cells (2550±634 
RFP+ cells, 1349±348 GFP+ cells per reaction, from three experiments) quantitative 
PCR (qPCR) was performed using Fast SYBR Green Master Mix kit (Applied 
Biosystems) according to manufacturer’s instructions. Briefly, 5-10 ng cDNA was 
mixed with a master mix containing 5’ and 3’ primers (50 nmol/L each; Table 15). 
qPCR was performed in ABI PRISM 7900HT Fast Real-Time PCR system (Applied 
Biosystems) on 384-well plate format according to the PCR program shown in Table 
16. qPCR analysis was performed using ΔΔCt method and GAPDH was used as the 
reference gene for normalization (Livak and Schmittgen 2001). 
 
Master Mix 
Number of samples 30x 
ddH2O 108 µl 
5' primer (10 µmol/L) 1.25 µl 
3' primer (10 µmol/L) 1.25 µl 
Sybr Master Mix 150 µl 
 
9 µl/sample 
cDNA sample 1 µl 
Total volume/sample 10 µl 
     
    Table 15. Composition of qPCR reaction. 
Initial denaturation 95 °C 1x 
Denaturation 95 °C 
40x Annealing 60 °C 
Extension 60 °C 
Final extension 60 °C 1x 
Inactivation 95 °C 1x 
 
     Table 16. qPCR protocol. 
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2.7.6 RNA sequencing 
RNA was isolated as described in section 2.7.1 and the quality was assessed with 
the Agilent Bioanalyzer 2100. Total RNA was subjected to library preparation 
(TruSeq Stranded Total RNA Sample Prep Kit from Illumina) and RNA-sequencing 
on an Illumina HighSeq-2000 platform (SR 50 bp; >25 Mio reads /sample). Sequence 
images were transformed with the Illumina software BaseCaller to bcl files, which 
were demultiplexed to fastq files with CASAVA (v1.8.2). Fastq files were mapped to 
GRCh38/hg38 using STAR 2.4 or TopHat2 (Kim et al. 2013) and Reads Per Kilobase 
of transcript per Million (RPKM) were calculated based on the Ensembl transcript 
length as extracted by biomaRt (v2.24) or Fragments Per Kilobase of transcript per 
Million (FPKM) calculated by Cufflinks (Trapnell et al. 2012). We only considered 
“protein_coding” transcripts for further analysis. Gene ontology (GO) analysis was 
performed through DAVID (Huang da et al. 2009). To determine cardiomyocyte, 
fibroblast and CPC specific genes the following algorithm was applied: (1) normalized 
counts of purified hES2.R26-derived cardiomyocytes (n=3) and fibroblasts from two 
different sources (foreskin and heart; n=3 from each source) and human GFP+ CPCs 
(n=3) were pooled and the differentially expressed genes (DEG, p<0.05) between 
cardiomyocyte, fibroblast and CPC pools determined; (2) log2 changes of DEG were 
calculated and genes omitted with a log2 difference lower than mean log2 of all 
cardiomyocyte genes; (3) resulting cardiomyocyte-, fibroblast-, and CPC-enriched 
genes were screened for RPKM values in adult healthy heart. Transcribed genes with 
RPKM <1 in adult heart were omitted. 
2.8 Cell based models of cardiomyocyte hypoxia 
To investigate possible cardioprotective activity of CPCs, we developed a new EHM 
injury model based on hypoxia/reoxygenation (H/R) or chronic hypoxia. Embryonic 
stem cells from ODD-Luc mice (refer to 2.1.2) or a newly generated human ODD-Luc 
reporter embryonic stem cell line (refer to 2.11) were used as cardiomyocyte sources 
for EHM construction according to the protocols outlined above. 
 
 
2. Materials and Methods 
39 
 
2.8.1 Imaging hypoxia in mouse ODD-Luc cardiomyocytes 
ODD-Luc fusion protein has been shown to be responsive to hypoxia and can be 
used as a noninvasive bioluminescence imaging technique to monitor the temporal 
kinetic of endogenous HIF-1α regulation in different cell types (Moroz et al. 2009, 
Viola et al. 2008). Being the main regulatory protein for adaptation of cellular 
response to hypoxia, identification of HIF-1α regulation may provide mechanistic 
insight into diseases like ischemia/reperfusion injury. To visualize and analyze the 
response to hypoxia in cardiomyocytes, we utilized the ODD-Luc x α-MHC-NeoR 
mESC line to give rise to ODD-Luc cardiomyocytes which ubiquitously express HIF-
1α-ODD-Luc fusion protein. ODD-Luc cardiomyocytes were incubated in hypoxia 
chamber (Invivo 400 workstation, Ruskinn, UK) under 1% O2 for 8-72 hours. After 
hypoxia treatment, ODD-Luc CMs were lysed with a lysis buffer (Dual-Luciferase® 
Reporter Assay Systems, Promega) diluted 1:5 with ddH2O water and supplemented 
with protease and phosphatase inhibitors (both diluted in 1:1000 dilution, see 
Appendix A1 for stock solutions) inside the hypoxia chamber. Thereafter, the 
enzymatic reaction depicted in Figure 13 was performed according to manufacturer’s 
protocol using Centro LB 960 Microplate Luminometer (BERTHOLD Technologies) 
and Microwin 2000 software (Informer Technologies).  
 
Figure 13. Bioluminescent reaction catalyzed by firefly luciferase. Luciferase activity assay 
involves oxidation of luciferin substrate in the presence of O2, ATP and Mg
2+
. Schematic adapted from 
the Promega user manual.  
2.8.2 Imaging hypoxia in mouse ODD-Luc EHM 
In the next step, ODD-Luc hypoxia reporter CMs (70%) and mEFs (30%) were 
utilized to construct ODD-Luc mouse EHM to monitor hypoxia at a tissue level. ODD-
Luc EHMs were incubated in 1% O2 for 1-72 hrs. Thereafter, ODD-Luc EHMs were 
transferred into PBS containing 1 mg/ml of luciferin (Caliper life sciences) and 
immediately visualized for bioluminescence development using LAS-3000 
COOH
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luminesence image analyzer (Fuji). Analysis of luminescence intensity was done by 
Image J software. 
2.8.3 Generation of ODD-Luc human embryonic stem cell line 
The plasmid ODD-Luciferase-pcDNA3 was a kind gift from the Kaelin lab (Dana-
Farber/Harvard Cancer Center). ODD-Luc transgene was cloned from the original 
plasmid into a pAAVS1 vector under the control of CAG promoter resulting in 
pAAVS1-CAG-ODD-Luc-EF1α-GFP donor vector. ODD-Luc hES2 cells were 
generated via transfection with the ODD-Luc expressing pAAVS1 donor vector in 
conjuction with pAAVS1 Trancription activator-like effector-nuclease (TALEN) pair 
plasmids following the principle as described in Figure 14. Briefly, TALE nucleases 
encoded by TALEN pair plasmids recognize and cut specific DNA sequences in the 
AAVS1 safe harbor genomic locus, facilitating homologous recombination of the 
transgene flanked by TALE recognizing sequences. The donor vector was 
constructed by Dr. Claudia Noack (Institute of Pharmacology and Toxicology, 
University Medical Center Göttingen) and transfection of hESCs was kindly 
performed by Krasimira Sharkova (Institute of Pharmacology and Toxicology, 
University Medical Center Göttingen). Next, puromycin selected ODD-Luc expressing 
hES cells (ODD-Luc hESCs) were differentiated into human cardiomyocytes (hCMs) 
giving rise to the formation of ODD-Luc hCMs.  
 
 




Figure 14. ODD-Luc hES cells generated using TALEN technology. pAAVS1 donor vector 
encoding for ODD-Luc under CAG promoter control and the GFP-puromycin (puro) fusion protein 
under EF-1α promoter control flanked by AAVS1 specific DNA sequences. TALE nucleases recognize 
and cut specific DNA sequences in AAVS1 genomic locus in hES cells, leading typically to 
homologous recombination of gene of interest in the targeted site. 
2.8.4 Hypoxia imaging in ODD-Luc human cardiomyocytes 
Human cardiomyocytes differentiated from ODD-Luc hESCs were dissociated as 
described above (section 2.1.3) and seeded on Matrigel™ (Corning, 1:30 diluted in 
PBS)-coated 6-well plates with a seeding density of 0.5 x 106 cells/well in hCM 
medium (Appendix A1). After 5-7 days of metabolic selection in hCM selection 
medium (Appendix A1) to reduce non-myocyte content, cardiomyocytes were 
cultured in 21% or 1% O2 for 4 hours and subjected to Luc-signal measurements as 
described above (section 2.8.1). 
2.8.5 Hypoxia/Reoxygenation injury in human EHM 
hEHMs generated from hCMs (70%) and hFFs (30%), so called hFF-EHMs were 
exposed to 1% O2 for 8-120 hours in DMEM SF-B27 medium (Appendix A1). After 
hypoxia exposure, hEHMs were incubated in 21% O2 in freshly prepared DMEM SF-
CMR medium (Appendix A1) to induce reoxygenation. In order to analyze 
cardioprotective paracrine effects of hCPCs and hFFs, hEHMs were treated with 
hCPC- or hFF-Conditioned medium (ConM; Appendix A1) during reoxygenation. 
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After H/R injury, cardiomyocyte content, structure and function were assessed. In 
addition, lactate dehydrogenase (LDH) release was assessed according to the 
manufacturer’s protocol (Lactate dehydrogenase activity assay kit, #MAK066, Sigma-
Aldrich) to estimate the amount of cell death. 
2.8.6 Chronic hypoxia injury in human EHM 
Next, we investigated the possible cardioprotective effect of hCPCs under chronic 
hypoxia stimulation for 120 hours in 1% O2. We developed another hEHM model 
mainly composed of hCMs and hFFs partially included with hCPCs, so called 
hFF+hCPC-EHM (input cell numbers [x106] per hEHM; hCM/hFF/hCPC: 
0.84/0.36/0.09). hFF- and hFF+hCPC-EHMs were incubated in DMEM SF-B27 
medium (Appendix A1) at 21% or 1% O2 without any medium change for 120 hours. 
Afterwards, hEHMs were subjected to isometric force measurements. In addition, 
myocyte content, structure and function were analyzed in hEHM co-cultures.  
2.9 Western blot analyses 
Response of human embryonic stem cell-derived cardiomyocytes (hCMs) to hypoxia 
was assessed by detection of HIF-1α stabilization using western blot technique. 
2.9.1 Protein isolation 
hCMs were seeded in Matrigel™ (Corning, 1:30 diluted in 1 X PBS)-coated 6-well 
plates within the density of 0.3 x 106 cells/well in hCM medium (Appendix A1) and 
subjected to 1% O2 for 0-72 hours. Cells were lysed with 500 μl lysis buffer (Dual-
Luciferase® Reporter Assay Systems, Promega)/well as described above (see 
section 2.8.1), followed by a short centrifugation step (16,000 x g, 10 seconds, at 4 
 C) to pellet cell debris. The supernatant was used for the Western blotting.  
2.9.2 Bradford assay 
Protein concentration was measured using the Bradford assay. Serial dilutions (in 
µg/ml: 0, 0.312, 0.625, 1.25, 2.5, 5) of bovine serum albumin (BSA; stock 
concentration of 1 mg/ml) in distilled water were used as reference. Absorbance of 
samples (5 µl) supplemented with Bradford dye (95 µl of 1:10 in sterile water diluted 
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dye) was measured in a 96-well plate at 595 nm (FlexStation 3 Multi-Mode Microplate 
Reader, Molecular Devices). The accuracy of the measurement was defined based 
on R2 of the standard curve. The experimental R2 value for this test was 0.96 (n=1 
experiment). Protein concentration was calculated based on the slope intercept 
formula.  
2.9.3 SDS-gel electrophoresis 
Proteins were seperated using 12% seperating gel (Appendix A1). The separating 
gel was poured in between two glass plates. The upper part of the gel was covered 
with isopropanol during polymerization. Upon polymerization of the gel, isopropanol 
was removed and washed with distilled water. Next, a stacking gel (Appendix A1) 
was poured on top of the separating gel with a comb placed inside. The comb was 
carefully removed upon polymerization.  
20 μg of protein was mixed with 6x Laemmli loading buffer (Appendix A1) and kept at 
95 °C for 3 minutes prior to loading. Samples (30-40 µl) and a standard protein 
ladder sample (The Precision PlusTM Protein KaleidoscopeTM protein, BIO-RAD) were 
loaded and run in Running buffer (Appendix A1) for ~2 hours at 100 V and RoT. 
Next, proteins were transferred from the SDS-gel to a polyvinylidene fluoride (PVDF) 
by electroblotting in Transfer Buffer for 1.5 hours at 100 V and 4 °C. 
2.9.4 Immunoblotting 
PVDF membranes, after proteins transfer, were incubated with blocking buffer 
(Appendix A1) for 1 hour at RoT. After a short washing step in PBS-T (PBS with 0.1% 
Tween-20), PVDF membranes were incubated with primary antibodies (HIF-1α from 
BD Transduction and β-actin from Sigma-Aldrich; see Appendix A3 for antibody 
dilutions) in blocking buffer overnight at 4 °C. After three additional washing steps in 
PBS-T, membranes were incubated with appropriate secondary antibodies (IgG-
HRP-conjugated, Dako, see Appendix A3 for antibody dilution) in blocking buffer 
overnight at 4 °C. After three washes in PBS-T for 15 minutes each, membranes 
were incubated with the substrate (SuperSignal® West Femto Trial Kit, Themofischer 
scientific) which catalyzes the activity of horseradish peroxidase to generate a 
chemiluminesence signal. The chemiluminesence signal was detected by a 
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VersaDoc™ XR Imaging System and the images were analzyed using Image Lab 
software from BioRad. 
2.10 Quantification of lactate release 
hCMs were seeded into 24-well plates (62.500 cells/well) in hCM medium (Appendix 
A1). Culture medium was changed with DMEM SF-B27 medium (Appendix A1) 
before incubation at 1% O2 for 0-72 hours. Prior to analysis, medium was collected in 
1.5 ml polypropylene tubes, centrifuged for 20-25 minutes at 16,000 x g to remove 
any cell debris. Supernatant was transferred into a new polyprolylene tube. 100 μl of 
medium was added into the master mix prepared according to manufacturer’s 
instructions (L-lactic acid UV-method, Boehringer/R-Biopharm). The complete 
mixture was transferred into plastic cuvettes to initiate the enzymatic reactions 
(Figure 15) and subjected to spectrophotometric measurement of NADH at 340 nm 
(Centro LB 960 Microplate Luminometer, BERTHOLD Technologies). Lactic acid 
concentration was calculated based on the equation described in the related 
protocol. 
 
Figure 15. Lactic acid catalyzing reaction. 1 L-Lactate is oxidized to pyruvate in the presence of 
NAD
+
 and L-Lactate dehydrogenase (L-LDH). 2 Pyruvate from reaction 1 is trapped in the presence of 
L-glutamate and Glutamate-Pyruvate transaminase, leading the eqilibrium in reaction 1 to be 
displaced in favor of pyruvate and NADH
+
. 
2.11 Quantification of intracellular ATP  
hCMs were seeded in matrigel (Corning, 1:30 diluted in 1x PBS)-coated 96-well 
luminometer plate within the density of 2.5 x 104 cells/well in hCM medium. Cells 
were put into 1% O2 for 0-72 hours following medium change with DMEM SF-B27 
medium (Appendix A1). Prior to analysis, ATP standards were prepared in each 96-
well plate with the concentrations ranging from 1 μM to 10 nM by serial ten fold 
dilutions. 100 μl of Cell titer Glo Reagent (mixture of Luciferin substrate and 
Luciferase) were added on top of the medium. The luminescence signal generated 
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was directly proportional to the amount of ATP present. ATP amount was calculated 
based on the ATP standard curve. All steps were performed according to 
manufacturer’s instructions (CellTiter-Glo® Luminescent Cell Viability Assay, 
Promega). 
2.12 Statistics 
Data are presented as arithmetic mean with standard error of the mean (SEM). 
Statistical analyses were done using two-tailed unpaired Student’s t-test, one-way 
ANOVA, and two-way ANOVA with indicated post hoc tests using GraphPad Prism5 






3.1 Characterization of CPCs in monolayer culture 
 
Cardiac progenitor cells (CPCs) derived from adult mouse (mCPCs) or adult human 
heart (hCPCs) were characterized for their expression of specific cell-type markers 
using PCR and flow cytometry. Additionally, transcriptome profiling of hCPCs was 
performed by RNA-sequencing (RNAseq) to gain broader insight into their origin and 
biological activity. 
3.1.1 Mouse CPCs show a mesenchymal phenotype  
Two previously reported types of CPCs from adult mouse heart, selected by surface 
markers - (1) v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog (c-Kit; 
c-Kit-mCPCs; kindly provided by Mark Sussmann; San Diego State University; 
(Fischer et al. 2009)) and (2) lymphocyte antigen 6a (LY6A; Sca-1-mCPCs; kindly 
provided by Antonio Bernad; CNIC-Madrid; (Izarra, 2014 #95)) - were characterized. 
c-Kit expression could not be confirmed by PCR (Figure 16B) or flow cytometry 
(Figure 16C) in either of the tested mCPCs in monolayer culture. Flow cytometry 
showed that most of the c-Kit-selected mCPCs were positive for Sca-1 and the 
mesenchymal cell markers platelet derived growth factor receptor, alpha polypeptide 
(PDGFRA) and endoglin (CD105; Figure 16C). Additional PCR analyses showed 
that both mCPC types (c-Kit- and Sca-1-CPCs) also express discoidin domain 
receptor tyrosine kinase 2 (Ddr2), indicating their mesenchymal origin (Figure 16B). 
The absence of the cardiomyocyte development implicated transcription factor, Nkx2-
5 suggested that both of these cell types were not committed towards a 





Figure 16. Characterization of mCPCs. A Morphology of c-Kit- and Sca-1-mCPCs in monolayer 
culture. B RNA expression of stem cell markers c-Kit and Sca-1, early cardiac marker Nkx2-5 and 
fibroblast marker Ddr2 in mouse cardiac fibroblasts (mCFs), Sca-1-mCPC and c-Kit-mCPC by PCR. 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used as housekeeping gene for loading 
control. C Flow cytometry characterization of c-Kit-mCPCs for the expression of the “stem cell 
markers” c-Kit and Sca-1 (LY6A) as well as mesenchymal cell markers PDGFRA and CD105. 
3.1.2 Human CPCs are morphologically distinct from fibroblasts 
Human CPCs (hCPCs) isolated based on the c-Kit surface marker were delivered in 
frozen aliquots from Coretherapix (Spain) as part of a collaboration within the EU FP7 
CARE-MI Consortium. hCPCs were used immediately after thawing for 
characterization without additional culture in our laboratory to avoid technical artifacts 
that could modify the expression profile and original phenotype of the cells. hCPCs 
were characterized in direct comparison with human fibroblasts (hFFs: human 




hCPCs and hFFs showed distinct cell morphologies in vitro. hCPCs seemed to 
display a more spreaded phenotype with frequent protrusions, while hFFs were more 
elongated (Figure 17). hCPCs and hFFs with stable expression of GFP were used. 
 
Figure 17. Morphologically distinct phenotypes in hCPC and hFF monolayer cultures. A hCPCs 
(plated after thawing upon receipt from Coretherapix) and B hFFs in brightfield (left), GFP 
fluorescence (middle) and merged (right) images. Scale bars: 100 μm.  
3.1.3 Human CPC pools contain mesenchymal/endothelial cells 
Similar as for the mCPCs, there was no c-Kit expression detected in hCPC on mRNA 
level, although they were originally isolated based on the c-Kit receptor. Interestingly, 
hFFs were positive for c-Kit on the mRNA level, but also not by flow cytometry. 
hCPCs showed no expression of the definitive cardiac markers cardiac troponin I 
(TNNI3) and cardiac actin (ACTC1). NKX2-5 was also not detected in contrast to 







Figure 18. Expression of cardiac cell markers in hCPCs. RNA expression of the “stem cell” marker 
c-Kit, cardiac transcription factors NKX2-5 and GATA4, cardiac markers TNNI3 and ACTC1, 
endothelial cell marker PECAM1 in hCMs, hCPCs and hFFs by PCR. GAPDH was used as 
housekeeping gene for loading control. 
Next, flow cytometry analysis of cell surface receptor expression confirmed that 
hCPCs lack c-Kit receptor expression (Figure 19). In line with the PCR data (Figure 
19), a small fraction of hCPCs expressed PECAM1 (7.3±3.7%, n=3/group). In 
addition, a larger fraction of the hCPCs were decorated by CD90 (35.6±9.9%, 
n=3/group) and CD105 (60%, n=1/group), indicating a mesenchymal phenotype 
(Figure 19). Given the fact that CD105 plays an important role in angiogenesis (Duff 
et al. 2003), partial expression of CD105 together with vessel associated marker 
such as PECAM1 in hCPCs might give a hint for angioblast-like characteristics of 
hCPCs in the heart. The absence of CD45 positive cells suggested there is no 











Figure 19. Flow cytometry characterization of hCPCs. Immunophenotype analysis for the 
expression of stem cell marker c-Kit (n=2/group), endothelial cell marker PECAM1 (n=3/group), pan-
leukocyte cell marker CD45 (n=2/group), mesenchymal cell markers CD90 (n=3/group) and CD105 
(n=1/group) in hFFs and hCPCs. The bar graph below shows quantification of percentage of positively 
stained cells for the markers mentioned above. Insets show the respective flow cytometry analyses 





Collectively, the PCR and flow cytometry data suggest that hCPCs comprise a 
heterogeneous population, composed of mesenchymal and endothelial cells. GATA4 
expression might indicate some cardiomyogenic potential within the hCPC population 
(Figure 18).  
3.1.4 Human CPCs exhibit a unique transcriptome profile 
The initial PCR and flow cytometry analyses indicated that hCPCs differ from human 
foreskin fibroblasts (hFFs) and comprise a heterogeneous population of 
mesenchymal/endothelial cells. RNAseq was performed to further corroborate and 
extend these findings. Transcriptomes from hCPCs, human cardiac fibroblasts 
(hCFs), human embryonic stem cell-derived cardiomyocytes (hCMs) and hFFs were 
compared (Figure 20). Principal component analysis (PCA) showed that hCPCs 
differ from fibroblasts (hFFs and hCFs) and cardiomyocytes, confirming their unique 
identity (Figure 20A). Comparative transcriptome analysis between hCPCs and 
fibroblasts revealed a set of differentially expressed genes (DEGs) specific for each 
cell type (hCPC: 1,528, hFF: 1,612, hCF: 1,270 genes; Figure 20B). Genes 
specifically expressed in hCPCs differently than hCFs and hFFs (1,528 genes 
highlighted with orange color in the Venn diagram) were clustered into certain 
functional groups by gene ontology analysis suggesting that hCPCs actively 
transcribe unique plasma membrane, cell adhesion, cytoskeleton, and extracellular 
proteins (Figure 20C). All hCPC specific DEGs with their classifications are 






Figure 20. Comparative transcriptome analysis. A Principal component analysis of gene 
expression in hFFs, hCFs, hCPCs and hCMs (n=3/group). B Venn diagram representing the number 
of differentially expressed genes (DEGs) (Gray: DEGs in hFFs and hCFs, Yellow: DEGs in hFFs and 
hCPCs, Red: DEGs in hCFs and hCPCs. Intersection of yellow and red circles (in orange) represent 
DEGs (1,528) specific to hCPCs. C Gene ontology enrichment analysis of hCPC-specific DEGs (1,528 
genes; represented in orange in the Venn diagram above). 
The RNAseq data were further utilized to better define the identity of hCPCs, by 
analyzing the expression level of genes typically expressed in specific cell 
populations in the heart: (1) cardiomyocytes, (2) fibroblasts, (3) smooth muscle cells, 
(4) endothelial cells, (5) pericytes and (6) perivascular MSC-like cells.  
hCPCs did not express the mature cardiac marker, TNNI3 and early cardiac marker 
NKX2-5, but GATA4 in comparison to hCMs, confirming the earlier PCR data (Figure 
21A). GATA4 was also detected in hCFs in line with published evidence (Furtado et 
al. 2014) (Figure 21A). hCPCs showed low levels of endothelial cell marker 




adhesion molecule (CDH5), CD31 (PECAM1) and kinase insert domain receptor 
(KDR; Figure 21B). Expression analysis of smooth muscle cell markers further 
indicated that they express smooth muscle actin (ACTA2), but not mature smooth 
muscle cell markers like desmin (DES) and myosin heavy chain 11 (MYH11; Figure 
21C). They expressed the fibroblast markers transcription factor 21 (TCF21) and 
periostin (POSTN) at lower levels, but higher level of DDR2 compared to hCFs 
(Figure 21D). Interestingly, they seemed to be positive for all the markers expressed 
in pericytes; especially MCAM and chondroitin sulfate proteoglycan (CSPG4) when 
compared to all other cell types as well as the PDGFR beta subunit (PDGRB; Figure 
21E). Lastly, hCPCs also showed markedly higher expression of perivascular 
mesenchymal stem cell (MSC)-like cells associated marker (Kramann et al. 2015) 





Figure 21. Expression profile of cardiac cell-specific markers. Data is from RNAseq datasets and 
displayed as RPKM (reads per kilobase of transcript per million mapped reads) values from the 
individual cell populations (hCMs, hCFs, hFFs and hCPCs; n=3/group). A Cardiomyocyte (CM) 
markers NKX2-5, GATA4, and TNNI3; B endothelial cell (EC) markers CDH5, PECAM1 and KDR; C 
smooth muscle cell (SMC) markers MYH11, DES and ACTA2; D fibroblast markers TCF21, DDR2 and 
POSTN; E pericyte markers MCAM, CSPG4 and PDGFRB; F perivascular MSC-like cell marker GLI1. 




Taken together, transcriptome profile analyses suggested a pericyte and MSC-like 
origin of hCPCs with little evidence for cardiomyocyte, smooth muscle, fibroblast or 
endothelial fate. 
3.2 Cardio-supportive effects of mouse CPCs in EHM 
Stromal cells play an important role in supplying key factors (e.g. extracellular matrix, 
growth factors, cytokines) for the formation of a cardiogenic niche (Christalla et al. 
2012, Tiburcy et al. 2011). Engineered heart muscle (EHM), as a model of heart 
muscle development in vitro, may be utilized as an experimental platform to gain 
insight into specific cardio-instructive properties of stromal cells, including CPCs. 
3.2.1 CPCs support functional maturation of EHM 
To investigate if mouse CPCs support cardiac muscle formation, EHMs were made 
from purified mouse ESC-derived cardiomyocytes (mCMs; 82±4% α-actinin positive, 
n=5; Figure 22A,B) and mouse adult heart derived c-Kit-mCPCs. In a first set of 
experiments the optimal myocyte/non-myocyte ratio was determined. mCMs and 
mCPCs were mixed in different ratios (CM/CPC) ranging from 100/0% to 50/50% 
respectively, keeping the total cell number the same. After 3 days of hydrogel 
consolidation inside custom-made molds, tissues were transferred onto static 
stretchers to be mechanically stimulated for functional maturation for the following 11 
days (Figure 22C).  
Macroscopic analysis of muscle morphology showed that EHMs composed of only 
cardiomyocytes were distinctly larger and softer than the EHMs supplemented with 
mCPCs or mouse cardiac fibroblasts (mCFs), supporting the previously identified role 
of stromal cells (CFs) for tissue compaction. mCPCs supported EHM formation 








Figure 22. EHM structure and function enhanced by mCPCs. A Cardiomyocytes dissociated from 
antibiotic-selected mouse cardiac bodies after spontaneous cardiac differentiation (red: α-actinin, blue: 
Hoechst nuclear staining) and B flow cytometry analysis after staining for sarcomeric α-actinin to 
determine cardiomyocyte purity (n=5). C EHM cell composition: cardiomyocytes (mESC-CMs) and 
mCPCs ratio were as indicated in the box; the culture as indicated for 3 days in custom-made molds 
for tissue consolidation, followed by 11 days of mechanical stimulation for functional maturation. D 
GFP fluorescence (mCPCs were GFP
+
) and brightfield images (top right) of EHM without CPCs (0%), 
30% mCFs and 30% GFP
+ 
mCPCs. E Cardiomyocyte structure and alignment in mEHM with 0% GFP
+
 
mCPCs and F 30% GFP
+
 mCPCs (indicated by arrows). G Force of contraction (FOC) generated in 
mEHM in response to increasing extracellular calcium concentration (n=7/group from two experiments, 
two-way ANOVA, *p<0.05).  
Immunostaining of EHMs without CPCs (CM/CPC; 100/0%) revealed that 
cardiomyocytes (red, α-actinin positive) remained round shaped in small clusters and 




(Figure 22E). Consistent with the underdeveloped structure of the cardiomyocytes, 
EHMs without mCPCs failed to develop any measurable force (Figure 22G). In 
contrast, EHM composed of cardiomyocytes supplemented with mCPCs showed 
enhanced alignment and sarcomere development. Accordingly, force of contraction 
(FOC) was markedly enhanced in EHM supplemented with >10% mCPC (Figure 
22F,G).  
We next wanted to scrutinize potential differential effects of mCPCs and fibroblasts 
on functional maturation of EHM. For this, a supplementation of mCMs with 30% 
mCPCs or mouse embryonic fibroblasts (mEFs) was performed. Indeed, EHMs 
generated with mCPCs produced FOC similar to the EHMs supplemented with 
mEFs, suggesting that mCPCs have comparable cardio-instructive properties as 
fibroblasts (mEF-EHM: 0.36±0.05 mN, mCPC-EHM: 0.29±0.04 at 3.2 mM calcium, 
n=16/group; Figure 23A). Interestingly, mCPC-EHM displayed markedly higher 
sensitivity to calcium, suggesting for a more immature calcium handling machinery 
when compared to mEF-EHM (mEF-EHM: 0.74±0.05 mM EC50 calcium, mCPC-EHM: 
0.53±0.22 mM EC50 calcium; p<0.05, n=16/group Figure 23B). 
 
Figure 23. Functional comparison of mCPC- and mEF-EHMs. A Force of contraction (FOC) 
generated in mCPC- and mEF-EHM under increasing extracellular calcium concentration in 
thermostatted (37 °C) Tyrode’s solution and electrical field stimulation (2 Hz; n=16/group). B Display of 
FOC as percent of maximal FOC to determine the EC50 for calcium in mEF-EHM and mCPC-EHM; the 




3.3 Enhanced paracrine support by genetic manipulation of mouse CPCs  
Paracrine factors are one of the key components contributing to the cardiogenic 
niche (Christalla et al. 2012). The paracrine activity of mCPCs may support cardiac 
function and could be augmented by overexpression of microRNA-133a. MicroRNA 
(miR)-133a is one of the muscle specific microRNAs that play an important role in the 
regulation of embryonic heart development and cell death (Meder et al. 2008).  
Further, it was observed that mCPCs overexpressing miR-133a enhance cardiac 
functions upon injection into the heart after myocardial infarction in a rat model (Izarra 
et al. 2014). Reduced cardiomyocyte death and hypertrophy as well as increase in 
the number of DNA-replicating cardiomyocytes were suggested as the possible 
mechanisms underlying the beneficial effect in vivo, which could have been mediated 
by enhanced paracrine activity in CPCs overexpressing miR-133a. To further 
scrutinize this hypothesis, we developed an EHM model with defined neonatal rat 
cardiomyocytes and mCPC composition (3:1 ratio). mCPCs were genetically modified 
to express miR-control or miR-133a. Purity of neonatal rat cardiomyocytes was 
enhanced by preplating (84±3% α-actinin positive, n=8), the remaining ~15% percent 
are mainly comprised of rat firbroblasts (Figure 24). mCPC supplemented EHM 









Figure 24. Purification of neonatal rat cardiomyocytes. Gating strategy of the flow cytometry 
analysis of cardiomyocyte purity is displayed. Forward (FSC) and sideward scatter (SSC) analyses 
were followed by gating living cells based on DNA signal intensity and signal width (Hoechst-nuclear 
staining). Cardiomyocytes were identified by specific labelling for α-actinin positive before and after 
myocyte enrichment by pre-plating (n=8/group from 8 experiments, unpaired t-test, *p<0.05).  
 
EHMs with miR-133a-CPCs developed significantly higher FOC (Figure 25B). The 
number of apoptotic cardiomyocytes (caspase-3 positive) was reduced at day 3, 
which resulted in a higher percentage of cardiomyocytes remaining in miR-133a-
EHM at day 12 when compared to miR-control-EHM (Figure 25C,D). Real-time PCR 
analysis of growth factor expression in mCPCs revealed that expression level of Igf-
1, Vegf, Hgf and bFgf, which are involved in cardiomyocyte survival, growth and 
proliferation, were all increased in miR-133a-EHM, suggesting an involvement of 
miR-133a in the paracrine activity of mCPCs (Figure 25E). Collectivley, this data 
supported the in vivo studies in providing addition evidence for genetically enhanced 









Figure 25. miR-133a enhanced paracrine activity of mCPCs. A EHM containing mCPC could be 
identified by GFP
+
 fluorescence; images were taken on culture day 12. B Force of contraction (FOC) 
generated in miR-control (n=6) and miR-133a-CPC-EHMs (n=6) in response to calcium. C 
Representative images of whole-mount caspase-3 staining in miR-control- and miR-133a-CPC-EHMs 
(left; α-actinin, red; activated caspase-3, white; DAPI-stained nuclei, blue; scale bars: 20 µm); bar 
graph (right): quantification of the percentage of caspase-3 positive cardiomyocytes in EHM at culture 
day 3; n>1,000 cells from three experiments. D Representative images of cardiomyocytes with miR-
control- and miR-133a-CPCs (left; α-actinin, red; antibody detected GFP, green; DAPI-stained nuclei, 
blue; scale bar: 20 µm); bar graph (right): quantification of the percentage of cardiomyocytes in EHM 
at culture days 3 and 12; n>1,000/group from two and three experiments. E Expression level of bFgf, 
Hgf, Igf-1 and Vegf in miR-control- and miR-133a-CPC-EHMs at culture day 3 and 12; PCR was 
performed by Alberto Izarra (n=3/group from three experiments). *p<0.05 by two-way ANOVA with 
Bonferroni post-hoc test (B) and unpaired, two-tailed Student’s t-test (C-E). Data was published in 
(Izarra et al. 2014). 
3.4 Human EHM model 
To investigate possible cardiogenic function of human CPCs (hCPCs), hEHMs using 
the same principles as in the mouse model were generated. Human cardiomyocytes 
were derived from human embryonic stem cells (HES2-RFP) after directed 
differentiation and metabolic selection (average cardiomyocyte purity: 89±3% α-
actinin+ cells; n=3, Figure 26A). In parallel, hEHMs were made with fibroblasts 









-non-myocytes. A Brightfield 
image of hCMs with a representative flow cytometry plot (right) with the identification of 
cardiomyocytes (sarcomeric α-actinin
+
). B Schematic representation of hEHM construction strategy 
with cell-type color-coding: hCMs RFP
+
 / hFFs GFP
+
 / hCPCs GFP
+









 hCPCs) under GFP and RFP fluorescence, with merged 
images (rightmost). Scale bar: 1 mm. 
 
Based on the fluorescence imaging of RFP and GFP positive cells in EHM sections, 
cardiomyocytes and fibroblasts were observed more randomly distributed within the 
hFF-EHM matrix, whereas hCPCs tended to cluster towards the surface of the 
hCPC-EHM (Figure 27A). This finding suggests that hCPCs have the property to 
migrate in EHM. Cardiomyocytes showed similar elongation and cross-striations in 






Figure 27. Cell distribution and cardiomyocyte morphology in hEHM. A Low magnification 
overview of RFP
+
 hCMs and GFP
+
 non-myocytes in hFF-EHM (left) and hCPC-EHM (right). B 
Orientation and structure of cardiomyocytes in hFF-EHM (left) and hCPC-EHM (right). 
(Cardiomyocytes: red, α-actinin
+
; hFFs and hCPCs: GFP
+
; nuclei stained with the DNA-binding dye 
Hoechst in blue). Scale bars: 100 µm. 
3.4.1 Contractile performance in human EHM 
hFF-EHM developed significantly higher FOC than hCPC-EHM (hFF-EHM: 0.67±0.08 
mN, hCPC-EHM: 0.43±0.03 mN at 4 mM calcium, n=29/group *p<0.05; Figure 28A). 
On the other hand, they showed similar sensitivity to calcium (hFF-EHM: 0.88±0.26 
mM EC50 calcium, hCPC-EHM: 0.97±0.37 mM EC50 calcium, n=29/group; Figure 
28B) suggesting similar maturation of calcium handling machinery. β-adrenergic 
stimulation with isoprenaline (1 µmol/L) significantly enhanced FOC development in 
both hEHMs at EC50 calcium concentration (increase in FOC from baseline: 91±14% 
in hFF-EHM, 61±9% in hCPC-EHM; n=29/group), with however no obvious difference 
between the investigated groups (Figure 28C). Both hEHM co-cultures responded to 
cholinergic stimulation (carbachol) with the anticipated decrease in FOC, with 




hFF-EHM (decrease in FOC: hFF-EHM: 17±2%, hCPC-EHM: 12±2%, n=29/group, 
*p<0.05; Figure 28C). 
 
 
Figure 28. hCPCs and hFFs supported EHM. A Force of contraction (FOC) generated in hFF- and 
hCPC-EHM in response to gradually increasing extracellular calcium concentrations. B FOC as 
percent of maximal FOC to determine the apparent EC50 for calcium in hFF- and hCPC-EHM; the EC50 
for the respective groups is marked by blue lines (n=29/group). C Response to isoprenaline (1 µmol/L) 
as percentage change in FOC at EC50 calcium and response to carbachol (10 µmol/L) as percentage 
change in FOC after treatment with isoprenaline (n=29/group, unpaired t-test, *p<0.05). 
3.4.2 Passive biomechanical properties in human EHM 
Besides the role of providing structural support and organization to the tissue, the 
biophysical properties of EHM may be affected by stromal cells. Stromal cells are key 
contributors to EHM stiffness (Naito et al. 2006). To identify whether hFFs and 
hCPCs influence tissue stiffness differentially, resting tension (ReT – diastolic force) 




Accordingly, FOC/ReT ratio was higher in hFF-EHM as compared to hCPC-EHM 
(2.5±0.3 vs. 1.5±0.2, n=28/group, unpaired t-test, *p<0.05; Figure 29B).  
   
Figure 29. Passive mechanical properties of hEHM. A Resting tension (ReT) at Lmax and B ratio of 
force of contraction (FOC) to ReT in hFF- and hCPC-EHMs (n=28 /group, unpaired t-test, * p<0.05). 
Lmax: length at maximum FOC.  
Taken together, histological and functional analysis of hEHMs suggested that hCPCs 
were able to support heart muscle formation in EHM, albeit less efficiently as 
compared to hFFs. Differences in hFF versus hCPC localization, i.e., homogeneous 
versus surface localization will require further investigations. 
3.4.3 Cardiomyocyte structure and function in human EHM 
To further investigate the underlying mechanisms leading to less functional 
development in hCPC-EHM, cardiomyocyte content, maturation and structural 
development were assessed in comparison to hFF-EHM.  
Cardiomyocyte amount in EHM was assessed through quantification of sarcomeric α-
actinin positive cells by flow cytometry. The number of cardiomyocytes recovered 
from EHM after 14 days of culture was similar between the groups (hFF- vs. hCPC-
EHM: 3±0.3 x 105 vs. 3.2±0.2 x 105, n=10/group from three experiments; Figure 30A) 
suggesting that the actual reason of lower FOC development in hCPC-EHM was not 
due to the muscle cell amount, but less FOC generation per cardiomyocyte  (hFF- vs. 
hCPC-EHM: 3±0.4 vs. 1.6±0.1 nN, n=3/group, from three experiments, *p < 0.05; 




maturation of cardiomyocytes in hCPC-EHM, the percentage of cardiomyocytes 
expressing Ki67 as a marker for maintained cell cycle activity in cardiomyocytes was 
analyzed. However, no significant difference was detected between the EHM co-
culture groups (hFF- vs. hCPC-EHM: 19±5 vs. 17±4%, n>1,000 cells/group from 
three experiments; Figure 30C). Next, cardiomyocyte size and actinin intensity were 
compared to assess their structural maturation in the EHMs by flow cytometry 
analysis. Cardiomyocytes were not different in size (n=10/group from three 
experiments; Figure 30D), but demonstrated almost 10% less sarcomeric α-actinin in 
hCPC-EHM compared to the cardiomyocytes in hFF-EHM (actinin signal 
intensity/cardiomyocyte relative to hFF-EHM group: 1±0.03 vs.0.91±0.04 in hCPC-
















Figure 30. Cardiomyocyte amount and phenotype in hEHM. A Number of cardiomyocytes (α-
actinin positive cells detected by flow cytometry) in hFF- and hCPC-EHM (n=10/group). B Force of 
contraction (FOC) per EHM-cardiomyocyte (maximum FOC at 4 mM of calcium concentration divided 
by total cardiomyocyte number in EHM; n=3/group, unpaired t-test, *p<0.05). C Representative images 
of whole-mount Ki67 stainings in hFF- and hCPC-EHM (left; red: α-actinin, white: Ki67 and blue: 
Hoechst stained nuclei); bar graph (right) with quantification of percentage of Ki67 positive 
cardiomyocytes at day 14, n>1,000 cells from three experiments. D Relative size of cardiomyocytes 
(FSC-A median of α-actinin positive cells by flow cytometry; n=10/group from three experiments; 
reference group: hFF-EHM). E Relative α-actinin intensity (median fluorescence intensity of α-actinin 
positive cells by flow cytometry, n=10/group from three experiments; reference group: hFF-EHM; 




Taken together, these findings suggest that the potential mechanism behind reduced 
contractile function in hCPC-EHM when compared to hFF-EHM could be suboptimal 
structural and functional maturation of cardiomyocytes. 
3.4.4 Human CPC retention in EHM 
Cell retention is generally low after intramyocardial injection (Tossios et al. 2008). 
Retention of hCPCs in EHM was determined by flow cytometry. Upon dissociation of 
the EHM into single cell suspension living cells were identified by flow cytometry 
based on the Sytox DNA binding dye exclusion; single cells were identified by 
Hoechst staining (Figure 31A). Next, color-coded cell fractions were separated 
based on their respective fluorescence signals (cardiomyocytes: RFP+, stromal cells: 
GFP+); potential cell fusion events should be revealed as double positive cells for 
RFP and GFP (Figure 31B). A marked reduction on GFP+ (hCPC or hFF) cell 
number was observed by hEHM culture day 14 (day 0: 3.6 x 105 GFP+ cells, hFF-and 
hCPC-EHM on culture day 14: 0.48±0.04 x 105 and 0.36±0.06 x 105 GFP+ cells, 
respectively; n=14/group from three experiments). Double positive cells were rarely 













Figure 31. Retention of non-myocytes in hEHM. A Flow cytometry gating strategy to determine 





; representative image on the left). B Left plot: flow 
cytometry gating protocol to separate RFP
+
 cardiomyocytes and or GFP
+
 non-myocytes (NMs: hFFs or 
hCPCs); middle panel: quantification of the number of GFP
+
 hFFs or GFP
+
 hCPCs at day 0 (input 
number) in comparison to the respectively isolated hFFs and hCPCs from EHM on culture day 14 





 cells; n=14/group); *P<0.05 vs. d0 by Student’s t-test. 
3.4.5 No evidence of cardiomyocyte transdifferentiation in human EHM 
To investigate whether hCPCs are able to differentiate into cardiomyocytes, EHM 
were digested into single cells and subjected to the following analyses: (1) flow 
cytometry analysis of α-actinin expressing GFP+ cells (Figure 32A), (2) fluorescence-
activated cell sorting (FACS) followed by qPCR for cardiac musle α-actin (ACTC1) 
transcipts in the RFP+ cardiomyocyte and GFP+ stroma cell pools (Figure 32B). 
The cardiomyocyte (actinin+) and non-myocyte populations could be clearly 




suggesting cell fusion or transdifferentiation in EHM culture; interestingly, there was 
no difference in the amount of actinin+/GFP+ cells in the hFF- and hCPC-EHM (hFF- 
vs. hCPC-EHM: 4.0±0.7% vs. 7.4±1.8%, n=6/group from four experiments; Figure 
32A). Given no evidence for transdifferentiation of hFFs, we concluded that the 
similarity of the amount of double positive cell populations in hFF- and hCPC-EHM 
was most likely due to false-positive antibody labelling in the non-myocyte pool. To 
further scrutinize this, RFP+ cardiomyocytes and GFP+ non-myocytes from culture 
day 14 hEHM were separated by FACS and independently subjected to RNA 
isolation followed by qPCR to analyze transcription of the cardiomyocyte specific 
ACTC1 gene. The data from this experiment indicated a 100-fold higher ACTC1 
abundance in the hCM pool in comparison to the respective hFF and hCPC pools 
(Figure 32B). Interestingly, ACTC1 transcript abundance was also 100-fold higher in 
the GFP+ cells isolated from EHM as compared to the input GFP+ populations. A 
separate qPCR amplification of RFP (unique cardiomyocyte label) suggested carry-
over during the separation of the GFP+ cell pools by FACS (Figure 32C). This notion 
was further supported by fluorescence microscopy of the separated cell pools with 
little, but detectable contaminating RFP+ cells in the GFP+-sorted cell population 
(Figure 32D). Taken together and despite some hints for non-myocyte differentiation 
or fusion we conclude that the most likely explanation for RFP+/actinin+ cells in the 
GFP+ hFF and hCPC pools would be cardiomyocyte carry-over. Single cell PCR and 
RNA-sequencing technologies may help to further identify whether 
transdifferentiation of hFFs or hCPCs had occurred in EHM. Nonetheless, it appears 
unlikely that these rare events contributed to the cardio-supportive effects of the non-










 cells digested from either hFF- or hCPC-EHM (n=6/group from four 
experiments). B FACS of RFP
+
 CMs (cardiomyocytes) and GFP
+
 NMs (non-myocytes) after digestion 
from EHM co-cultures and qPCR analysis of cardiac actin gene expression in the separately sorted 
pools (normalized to hFFs at culture day 0; n=2/group). C Electrophoretic separation of RFP 
transcripts (specific band at 227 bp) after qPCR amplification in hCM, hCPC and hFFs at culture day 0 
and in GFP-sorted hCPCs and hFFs at EHM culture day 14. D GFP and RFP fluorescence signals on 





3.5 Modeling hypoxic injury in EHM 
Experimental hypoxia/reoxygenation (H/R) models are useful tools to investigate 
cardio-protective strategies against myocardial infarction (Portal et al. 2013). To 
investigate cardio-protective effect of hCPCs, the aim was to first develop EHM 
models of acute and chronic hypoxia-dependent injury.  
3.5.1 Hypoxia response in human cardiomyocytes 
To characterize the effect of hypoxia on the physiological state of cardiomyocytes, 
HIF-1α protein stability and metabolic modifications were analyzed under hypoxia 
(1% O2) exposure for 8-72 hrs. Cardiomyocytes responded to hypoxia with HIF-1α 
stabilization after 8 hrs of hypoxia exposure (Figure 33A). Metabolic activity changed 
accordingly as exemplified by a drop in intracellular ATP amount (Figure 33B). In 
agreement with these findings, a gradual increase in lactate was detected starting 
after 8 hrs of hypoxia (Figure 33C). Accumulation of lactate suggests that human 
cardiomyocytes shift their energy metabolism from aerobic respiration to anaerobic 
gycolysis. Constant ATP levels at 8 and 24 hrs of hypoxia suggested that the 
cardiomyocytes seem to adapt their metabolism to hypoxia within this time frame. 
Extended hypoxia (72 hrs) appeared to cause hypoxic damage, leading to a drop in 








Figure 33. Metabolic adaptation of human cardiomyocytes under hypoxia. A HIF-1α protein 
abundance by Western blot detection. B Intracellular ATP amount and C released lactate into the 
culture medium (n=4-5/time-point; 
*
p<0.05 as indicated by one-way ANOVA, Dunnett’s multiple 
comparison test).  
3.5.2 Hypoxia response in human EHM 
hFF-EHMs were exposed to 1% O2 for 8-120 hrs. Lactate release was increased after 
8 hrs of hypoxia, reaching maximal levels at 72 hrs (Figure 34). This was in line with 
the lactate release profile observed in human cardiomyocytes under hypoxia. Note 
that lactate release was also observed in EHM developed under 21% O2 (“normoxia”) 
without medium exchange reaching similar levels as observed in the hypoxic EHM 
after 120 hrs in culture. Thus, the hypoxia related cell damage occured within the first 
96 hrs of hEHM culture at 1% O2. Beyond that time window, nutrient depletion may 







Figure 34. Lactate production by hEHM cultured under normoxia and hypoxia. Lactate 
accumulation in hEHM culture medium under normoxia (21% O2) and hypoxia (1% O2) for 8-120 hrs 
with no medium change (n=4/group, *p<0.05 by two-way ANOVA with Sidak’s multiple comparison 
test). 
3.5.3 Hypoxia/Reoxygenation damage in human EHM 
hEHMs were exposed to different durations of hypoxia (H; 1% O2; 8-120 hours) 
followed by 24 hrs of reoxygenation (R; 21% O2) to identify whether 
hypoxia/reoxygenation (H/R) damage could be simulated (Figure 35A). We did not 
observe any reduction in FOC of hEHMs under hypoxia for 8-72 hrs (8 and 24 hrs 
time points not shown). However, reoxygenation after 72 hrs hypoxia resulted in a 
marked reduction in EHM contractility (Figure 35B). Conversely, 120 hrs of hypoxia 
caused EHM damage, which could not be further aggravated by reoxygenation 









Figure 35. Development of a hypoxia/reoxygenation injury hEHM model. A Schematic overview 
of the experimental setting of H/R injury in hEHMs. hEHMs incubated in 1% O2 for 72 or 120 hrs and 
reoxygenated in 21% O2 in an oxygenated fresh medium for 24 hrs and subsequently analyzed at 
functional and structural level. B Force of contraction (FOC) in hEHM after only 72 hrs of hypoxia or 72 
hrs hypoxia followed by 24 hrs of reoxygenation (n=5-6/group from two experiments, unpaired t-test, 
*p<0.05). C FOC in hEHM after only 120 hrs of hypoxia or 120 hrs of hypoxia, followed by 24 hrs of 
reoxygenation (n=8/group from two experiments, unpaired t-test, *p<0.05). hEHMs at 0 hr of hypoxia 
served as normoxia control for the corresponding experimental conditions.  
Interestingly, cardiomyocyte quantity per EHM was significantly reduced after 72 hrs 
(Figure 36A), without an obvious impact on EHM contractility (Figure 35B). 
Reoxygenation aggravated the cardiomyocyte loss after 72 hrs of hypoxia (Figure 
36A), which was in-line with the observed functional decay (Figure 35B). As 
expected, chronic hypoxia stimulation (120 hrs) resulted in a pronounced decrease in 




cardiomyocyte survival after enzymatic digestion from EHM subjected to 24 hrs of 
reoxygenation. Note that the discrepancy between contractile performance and 
cardiomyocytes count after 72 hrs hypoxia could result from a higher susceptibility of 
hypoxic cardiomyocytes to enzymatic EHM digestion. We further employed a LDH 
activity assay to evaluate cell damage upon reoxygenation and found that extended 
reoxygenation (24 hrs) caused substantial damage (Figure 36B).  
 
Figure 36. Validation of the hypoxia/reoxygenation injury hEHM model. A Percentage of total 
cardiomyocytes after 72 hrs (72 H; n=3-4/group, unpaired t-test, *p<0.05) and after 120 hrs of hypoxia 
(120 H; n=6-8/group, unpaired t-test, *p<0.05 vs. Ctr), with the following 24 hrs of reoxygenation 
induction (72H/R or 120 H/R). B LDH activity as an indicator of cell damage/death during 24 hrs of 
reoxygenation following 72 hrs of hypoxia (n=2-3/group). Ctr: Control EHM incubated under normoxia 
for the corresponding experimental condition.  
Collectively, these data define the time windows for the simulation of hypoxic (120 
hrs 1% O2) and hypoxia/reoxygenation (72 hrs 1% O2 followed 24 hrs 21% O2) 
damage in human EHM.   
3.6 Assessment of the protective effects of human CPCs in EHM  
hCPCs are tested clinically for myocardial protection after myocardial infarction 
(Makkar et al. 2012). Here, we aimed at investigating potential cardio-protective 






3.6.1 No evidence for paracrine protection by CPCs  
hEHMs were exposed to H/R injury as established before (see 3.5.3) and exposed to 
either hCPC- or hFF-conditioned medium (ConM) during reoxygenation after 4 weeks 
of regular EHM culture (Figure 37A). As expected, H/R significantly reduced hEHM 
function markedly compared to normoxia control EHM (EHM-Ctr: continuously 
incubated at 21% O2). hEHM treated with hCPC-ConM did not show any rescue from 
H/R injury. Interestingly, hFF-ConM treatment during reoxygenation partially 
preserved contractile function of hEHM, reducing the injury effect by ~50% (Figure 
37B). H/R injured hEHMs (EHM H/R: treated with fresh medium) showed increased 
calcium sensitivity (EC50: Ctr. 0.7±0.1, n=9/group vs. H/R 0.3±0.1 mmol/L, n=4/group, 
p<0.05 by Student’s t-test; Figure 37C). hFF-ConM and hCPC-ConM shifted the 
calcium sensitivity in H/R towards Ctr levels with a slightly more enhanced effect in 
hFF-ConM (fold difference in EC50 in mmol/L: hFF-ConM 0.6±0.1, n=9/group vs. 
hCPC-ConM 0.5±0.1 mmol/L, n=5/group; Figure 37C). The latter finding needs 
further investigations on the molecular level to determine whether calcium-
homeostasis is indeed altered and involved in the functional deterioration as well as 





Figure 37. Effects of conditioned medium on EHM function upon H/R injury. A Schematic 
overview of the experimental design to test potential protective mechanisms of hCPC-conditioned 
culture medium. Following 72 hrs of hypoxia, hEHMs were exposed to 24 hrs of reoxygenation in the 
presence of hCPC- or hFF-Conditioned medium (ConM); regular medium exchange in the H/R model 
served as “injury” control; standard hEHM cultures served as “healthy” controls. B Force of contraction 
(FOC) and C calcium sensitivity in Ctr (normoxia), H/R (H/R injury), H/R+hCPC-ConM and hEHM-
H/R+hFF-ConM (n=9-10/EHM from three experiments, *p<0.05 vs. Ctr. by two-way ANOVA, Dunnett’s 
multiple comparison test B and Student’s t-test C. 
Consistent with the data on EHM function (Figure 37B), H/R caused a significant 
reduction in cardiomyocte content and reduced contractile function. Similarly as 
reported for EHM function, there was no protection from cardiomyocyte death upon 
H/R injury by hCPC-ConM. Conversely, cardiomyocyte amount and contractility as a 
fuction of cardiomyocyte number was markedly enhanced in hFF-ConM treated 
hEHMs (Figure 38A,B), suggesting that hFFs rather than hCPCs were able to 





Figure 38. Effects of conditioned medium on EHM cardiomyocyte content upon H/R injury. A 
Cardiomyocyte number (n=8-10/group) and B force of contraction (FOC) as a function of 
cardiomyocyte content in Ctr, H/R, H/R+hFF-ConM and H/R+hCPC-ConM EHM. n=3/group; *p<0.05 
vs. Ctr by one-way ANOVA with Dunnett’s post-hoc test.  
To investigate whether H/R impaired the responsiveness to β-adrenergic stimulation 
the response to maximally effective isoprenaline (1 µmol/L) was tested.  These 
analyses showed a markedly depressed isoprenaline response in H/R treated EHM 
irrespective of the attempted conditioned medium rescue (Figure 39). 
 
Figure 39. Impaired β-adrenergic signaling in hEHM after H/R injury. Force of contraction (FOC) 
in percent of the inotropic effect induced by isoprenaline in control EHM at EC50 calcium 





3.6.2 Discrimination of paracrine effects by transcriptome profiling 
CPCs have been reported to possess paracrine potency to reduce cell death and 
support cardiomyocyte proliferation as well as play angiogenic (Chimenti et al. 2010, 
Li et al. 2012, Malliaras et al. 2013) and anti-inflammatory roles (Liu et al. 2014). To 
gain preliminary insight into the specific paracrine activity of hCPCs and hFFs and to 
explain the differential effect of conditioned medium, a number of growth factors and 
cytokines that are involved in cell survival, proliferation, angiogenesis and 
inflammation (see Appendix A6 for the full list of growth factors and cytokines) were 
selected and screened in the pool of differentially expressed genes from RNAseq 
data in hCPCs vs hFFs. Several clusters of genes were detected that were 
differentially expressed between hCPCs and hFFs (Figure 40A). Ontology 
enrichment identified that hCPC genes involved in angiogenesis and immune 
response were strongly regulated. Paracrine factors up-regulated in hFFs were more 
involved in the regulation of cell proliferation and survival (Figure 40A). We also 
confirmed the expression of the specific growth factors FGF-2, VEGF, IGF-1, HGF 
and PDGF – all with a known effect on cell proliferation, survival and migration – by 
PCR (Figure 40B). The enrichment of transcripts encoding for cell survival 
enhancing factors in hFFs was in line with their effects on cardiomyocyte survival in 
EHM upon H/R injury (Figure 38A). Given the major effect of hFF-ConM on the 
protection of cardiomyocyte function after H/R injury, it might be worth to investigate 
the mechanism behind the impairment in cardiac function, first and further screen for 
related cardio-supporting factors secreted from these fibroblasts. On the other hand, 
possible pro-angiogenic and inflammation modulatory role of hCPCs according to the 
RNAseq data might provide a possible mechanism for their ameliorating effect on 
tissue injury in vivo (Liu et al. 2014). No effect in EHM may be attributed to the lack of 



















Figure 40. Paracrine activity in hCPCs and hFFs. Heatmap analysis of 
genes encoding for paracrine factors involved in cell survival, proliferation, 
angiogenesis and inflammation in hCPCs and hFFs; on the right functional 
annotation of differentially expressed genes in gene clusters; Red and blue 
reflect high and low expression levels, respectively as scaled in color key 
bar (n=3/group). B PCR analysis of a selected number of transcripts 
encoding for growth factors with implications in cardiac homeostasis: FGF2, 










3.6.3 Cardio-protective effects of CPCs in EHM exposed to chronic hypoxia 
To investigate whether or not hCPCs elicit a cardio-protective role under chronic 
hypoxia and following the hypothesis that hCPCs may elicit their effects only under 
more physiological conditions, EHMs were constructed from CMs (65%) and hFFs 
(28%) with the addition of hCPCs (7%) and exposed to 1% oxygen for 120 hrs after 4 
weeks of regular EHM culture (Figure 41A). Chronic hypoxia decreased FOC by 
almost 68±6% in hFF-EHM in agreement with the findings reported before (refer to 
Figure 35C). Interestingly, hFF+hCPC-EHM already under normoxic control 
conditions presented with slightly enhanced forces and an only mildly reduced FOC 
under chronic hypoxia (Figure 41B). Calcium sensitivity (average EC50: 0.34±0.03 
mmol/L) was similar in all groups suggesting differential effects of H/R and chronic 











Figure 41. Effects of CPC in EHM tri-cultures upon chronic hypoxia. A Schematic overview of the 
experimental design to test potential protective mechanisms of hCPCs on EHM composed of hFFs 
and CMs with or without hCPC supplementation. Following 4 weeks of regular culture, EHMs were 
exposed to 1% O2 for 120 hrs (hypoxia: Hyp) or maintained under 21% ambient O2 (Ctr) without 
culture medium exchange; hFF-EHM: 70% CMs and 30% hFFs; hFF+CPC-EHM: 65% CMs, 28% 
hFFs, 7%CPCs. B Force of contraction (FOC) and C calcium sensitivity in Ctr in the indicated groups; 
n=4/group, *p<0.05 by two-way ANOVA with Tukey’s multiple comparison post hoc test. 
No obvious difference was detected in cardiomyocyte amount between hFF- and 
hFF+hCPC-EHM under normal conditions. After chronic hypoxia, cardiomyocyte 
content was significantly decreased in hEHM with or without hCPC supplementation 
(Figure 42A); however, a trend to a better cardiomyocyte preservation was apparent 
in the hCPC supplemented EHMs. α-Actinin content and function per cardiomyocyte 
were preserved only in hFF+hCPC-EHM, suggesting a beneficial effect of hCPCs on 
cardiomyocytes in EHM tri-cultures (Figure 42B,C). Further investigations are 






Figure 42. Enhanced cardiomyocyte survival and function in EHM tri-cultures. Experimental 
conditions were as outlined in Figure 41A with EHM exposed to chronic hypoxia. A Cardiomyocyte 
number/EHM, B cardiomyocyte α-actinin content by mean fluorescence intensity measurements and 
C FOC as a function of EHM cardiomyocyte content (n=4/group same EHM as in Figure 46); *p<0.05 
as indicated by two-tailed, unpaired Student’s t-test.  
3.7 Development of a genetic hypoxia indicator model   
Cell and tissue hypoxia models would benefit greatly from tools for life-cell imaging of 
cell oxygenation states. First steps towards the ultimate goal to develop a hEHM 
model comprising cardiomyocyte-specific hypoxia sensors are described below. 
3.7.1 Hypoxia sensing in ODD-Luc mouse cardiomyocytes  
In order to identify the biological response of cardiomyocytes to hypoxia, a genetically 
modified mouse ODD-Luc ESC line (see Appendix A4) was utilized to generate ODD-
Luc mouse cardiomyocytes. The ubiquitously expressed reporter in this ODD-Luc 
ESC line comprised a HIF-1α oxygen-dependent degradation domain (ODD) fused to 
a firefly luciferase (Luc). Stability of the ODD-Luc fusion protein depends on the 
oxygenation level. Under normoxia, prolyl residues in the ODD domain are 




results in ubiquitination and rapid degradation of the protein. Under hypoxia, reduced 
PHD enzyme activity leads to stabilization of HIF-1α (Schofield and Ratcliffe 2004). 
According to this system, any decrease in oxygen amount should lead to stabilization 
of the ODD-Luc protein and thus an increase in Luc signal intensity (Figure 43A). 
To validate whether the response to hypoxia can indeed be measured in this cell-
based reporter model, ODD-Luc cardiomyocytes were exposed to 1% O2 for 1-72 hrs 
and Luc signal was analyzed at multiple time-points. ODD-Luc cardiomyocytes 
showed a significant increase in Luc signal with peak intensity at 24 hrs (Figure 
43B). Luc signal intensity showed a good correlation with the abundance of ODD-Luc 
protein and endogenous HIF-1α protein (Figure 43C). Elevation of PHD2 protein at 
24 hrs, as a negative feedback mechanism may be an additional explanation for the 
decrease in endogenous HIF-1α and ODD-Luc protein in extended culture (Figure 
43C). Collectively, these findings support the use of the ODD-Luc model in sensing 





Figure 43. Validation of ODD-Luc hypoxia reporter in cardiomyocyte culture. A Schematic 
representation of the mechanisms regulating the stability of ODD-Luc fusion protein based on ambient 
oxygen levels (21% O2: hydroxylation of prolyl residues in HIF-1α-ODD results in proteosomal 
degradation of the ODD-Luc fusion protein, 1% O2: no post-translational modification in HIF-1α-ODD 
and stabilization of ODD-Luc fusion protein). B Time-dependent Luc signal development in 
antibiotically selected ODD-Luc cardiomyocytes (mouse model) upon exposure to 1% O2 for 1-72 hrs 
(n=6/group). C Protein expression of endogenous HIF-1α, ODD-Luc fusion protein, PHD2 protein, 
firefly luciferase (FL) and β-tubulin using western blot (provided by Anke Zeiseniss; Institute of 






3.7.2 Hypoxia sensing in ODD-Luc mouse EHM  
ODD-Luc cardiomyocytes were utilized to generate EHMs with genetically naïve 
fibroblasts, based on the mouse EHM protocol as described previously (section 
2.3.2). ODD-Luc EHMs showed the highest signal at 24-48 hrs after the induction of 
hypoxia with a subsequent signal decrease (Figure 44A). Reoxygenation of ODD-
Luc EHMs at 21% O2 after 4 hrs of hypoxia rapidly diminished the Luc signal intensity 




Figure 44. Hypoxia and repoxygenation responses in ODD-Luc EHM. A Time-dependent Luc 
signal development in ODD-Luc EHM during hypoxia (1% O2) for 1-72 hrs (n=3/time point). B Time-
dependent reduction of Luc signal in ODD-Luc EHM after reoxygenation following 4 hrs of hypoxia 
(n=3/time-point). Panels below display signals recorded from representative ODD-Luc EHM (blue 
indicates low and red indicates high Luc signal). Data was published in (Hesse et al. 2014). 
3.7.3 Hypoxia sensing in human cardiomyocytes 
After obtaining proof-of-concept in the mouse model that the ODD-Luc reporter 
system can be used as a tool to monitor tissue oxygenation and hypoxia response, 
we attempted to establish the same system in a human model. For this purpose, 
ODD-Luc hESCs were generated using TALEN technology. Briefly, wild-type hESCs 
were targeted with pAAVS1-CAG-ODD-Luc-EF1α-GFP donor vector (section 2.8), 
which was generated by Dr. Claudia Noack and pAAVS1 TALEN Left and Right 




expressing human cardiomyocytes (ODD-Luc hCMs). ODD-Luc hCMs were validated 
for their hypoxic response with significantly higher expression of Luc signal after 4 hrs 
of hypoxia (1% O2) exposure (Figure 45). In future experiments, we intend to use 
these ODD-Luc hCMs to generate ODD-Luc hEHMs as a human heart muscle model 
to gain a better understanding on their response to hypoxia and reoxygenation. 
 
Figure 45. Hypoxia response in ODD-Luc human cardiomyocytes. Luc-signal development in 





Cardiac progenitor cells (CPCs) were identified in the heart based on Sca-1 and c-Kit 
surface markers (Beltrami et al. 2003, Oh et al. 2003). Despite some evidence for 
Sca-1-like cells in the human heart (Smits et al. 2009), c-Kit has been used as a 
common marker for CPCs in the human heart. The biological relevance of CPCs is 
under debate since their introduction more than 10 years ago (Beltrami et al. 2003) 
with several clinical trials being underway to identify the therapeutic utility of CPCs in 
the human heart (Bolli et al. 2011, Makkar et al. 2012). The interpretation of the 
biological relevance of CPCs in the heart is diverse, ranging from being transiently 
extravagated leukocytes or mast cells (Kubo et al. 2009) to being resident 
progenitors with strong cardiomyogenic activity (Ellison et al. 2013). Despite the 
ongoing clinical trials, phenotypic characterization and the perceived mode of action 
of CPCs are still under debate (Chong et al. 2014). The aim of this thesis was to 
make use of the EHM platform to scrutinize the biological activity of CPCs. The 
following specific hypotheses were tested: 
1) CPCs support functional heart muscle formation in vitro. 
2) CPCs elicit cardioprotective effects upon hypoxic injury.  
The key results are summarized below: 
1) CPCs are phenotypically distinct from fibroblasts. 
2) Human CPCs contain a pericyte transcriptome signature. 
3) CPCs and fibroblasts show a similar function as to the support of EHM formation. 
4) Paracrine activity of CPCs can be enhanced by enforced miR-133a expression. 
5) No evidence for CPC transdifferentiation into cardiomyocytes could be obtained. 




7) Fibroblats, but not CPCs protected from hypoxia/reoxygenation injury. 
8) CPCs protected EHM under chronic hypoxia. 
9) Novel tools for imaging of cardiomyocyte oxygenation could be established. 
4.1 Characterization of CPCs 
Phenotypic characterization of c-Kit-CPCs isolated from adult mouse and human 
heart revealed that they do not express c-Kit, although they were isolated based on 
c-Kit expression. It is likely that the CPCs lost their c-Kit expression in culture over 
time, as observed in muscle-derived stem cells, which change their phenotype 
immediately after being isolated (Jankowski et al. 2001). Different types of CPCs 
have been characterized by expression of different cell surface markers, so far. 
Whether these CPCs represent unique cell types or are related to each other is still 
under debate (Torella et al. 2008). PDGFRα+/Sca-1+ mesenchymal stem cell (MSC)-
like cells have been reported to exist in the adult mouse myocardium, with the 
potential to differentiate into three cardiac lineages. These cells were suggested to 
originate from epicardium and express c-Kit in a small subset (Chong et al. 2011). In 
our study, ~90% of mouse c-Kit-CPCs were found to be PDGFRα+/Sca-1+ as well as 
CD105+, indicating a mesenchymal/endothelial origin. Furthermore, lack of Nkx2-5 
expression, as an early cardiac marker suggested that these CPCs were not 
committed to the cardiomyocyte lineage. Conversely, PDGFRα+/Sca-1+ cells have 
been related to epicardial progenitors, which are mainly involved in the constitution of 
the vascular compartments of the developing heart, including smooth muscle cells 
and pericytes (Kennedy-Lydon and Rosenthal 2015).   
Pericytes are multipotential MSC-like cells that are positive for several distinct 
markers (MCAM, CSPG4, PDGFRβ, α-SMA) as well as more broadly expressed 
mesenchymal cell markers including CD90, CD73, CD105, CD44 and can apparently 
be induced to differentiate into cardiomyocytes and smooth muscle cells (Chen et al. 
2013, Crisan et al. 2008). Interestingly, human CPCs (hCPCs) showed a marked 




phenotype. However, detection of PECAM1 expression in hCPCs, although at a low 
abundance, would not be fully compatible with this hypothesis (Chen et al. 2013).  
Adventitial cells are another type of MSC-like progenitors expressing the 
endothelial/hematopoietic progenitor marker CD34 and mesenchymal cell markers 
(e.g. CD90, CD73, CD105 and CD44) with a  potential  to differentiate into 
endothelial-like and smooth muscle cells (Crisan et al. 2012). hCPCs did not express 
CD34. However, when compared to other cell types, hCPCs demonstrated an 
elevated expression of GLI1, which has recently been shown as a new marker to 
identify perivascular progenitors in the pericyte niche (Kramann et al. 2015). Although 
these cells are supposed to be negative for pericyte markers, they can indeed gain 
expression of pericyte-specific and smooth muscle cell-specific phenotypes (e.g. α-
SMA+) depending on in vitro and in vivo conditions (Kramann et al. 2015). In this 
respect, if hCPCs are true GLI1+ perivascular progenitors, this may explain the 
reason why they seem to show a high heterogeneous expression profile in vitro.  
Mesoangioblasts resemble another blood vessel associated stem cell type, with 
apparent multipotential characteristics (Crisan et al. 2008). These cells can show 
heterogeneous characteristics with partial expression of endothelial cell, pericyte, 
perivascular progenitor markers, as well as c-Kit. Consistent with the heterogeneous 
gene expression profile in hCPCs, cardiac mesoangioblasts might be another 
candidate in describing the lineage identity of hCPCs. 
Taken together, although each progenitor is defined by a combination of certain 
markers, these markers seem to be shared between different cell types (pericytes, 
adventitial cells and mesoangioblasts) suggesting that they may actually represent 
different intermediate forms of the same stem cell population in the heart. In this 
perspective, it is difficult to put CPCs under a specific class of stem cell population 
defined, so far. However, our phenotypic analysis suggests that they match closely 






4.2 Human CPCs might have an epicardial origin 
c-Kit+ cells were identified to be located predominantly in the subepicardium of the 
right atria and adjacent to myocardial intersititium in the heart (Chong et al. 2013, 
Keith and Bolli 2015, Limana et al. 2007, Limana et al. 2010).  These subepicardially 
located c-Kit+ cells are believed to be epicardial progenitors expressing epicardial 
developmental genes (e.g. Wt1 and Tbx18) during embryonic heart development and 
myocardial infarction (Limana et al. 2010). Given the fact that hCPCs in our study 
were originally isolated from the right atrial appendage, it is likely that they might be 
representing a subgroup of in vivo c-Kit+ progenitors subepicardially located in the 
right atria of the adult human heart. 
In addition, epicardial progenitors are normally derived by a process called ‘’epithelial 
to mesenchymal transformation’’ (EMT), whereby they develop a mesenchymal 
phenotype (Keith and Bolli 2015). In our study, we showed that not all, but a certain 
fraction of hCPCs present expression of mesenchymal markers; 36% CD90+ and 
60% CD105+, suggesting conversion to a mesenchymal transition state. Considering 
that the c-Kit receptor plays an important role in cell survival, migration and 
proliferation (Lennartsson and Ronnstrand 2012), c-Kit expression might have 
enabled progenitor cells to actively migrate towards the myocardium and gain an 
intermediate phenotype during the EMT process. Epicardial progenitors that undergo 
EMT highly contribute to vascular and interstitium compartments with little evidence 
of cardiomyocyte differentiation (Keith and Bolli 2015). In line with this, hCPCs did not 
show any late (cardiac actin and cardiac troponin I) or early cardiac marker (Nkx2-5) 
expression, but only enhanced GATA4. Furthermore, a small fraction (10%) of 
hCPCs were PECAM1+ as an indication for their vasculogenic potential. Moreover, 
relatively higher expression of EMT associated proteins; periostin and TCF21 in 
hCPCs can be considered supporting evidence for a epicardial origin. Considering 
the role of epicardium in the development of vascular compartment in the heart, it is 
likely that hCPCs may represent a subgroup of vascular associated progenitors 
migrated from the epicardium and localized in tunica adventitia.  
On the other hand, as demonstrated by gene ontology analysis of differentially 




adhesion, actin cytoskeleton organization, thereby cell migration (Appendix A5; e.g. 
Ras homology [Rho] GTPase family members RhoGTPase activating and 
RhoGTPase target genes as well as talin 1 [TLN1]). Considering the fact that c-Kit+ 
epicardial progenitors are highly invasive migrating from the epicardium to 
mesoethelial layer during EMT process (Keith and Bolli 2015), it can be speculated 
that these hCPCs might have been derived from these epicardial progenitors 
preserving their intrinsic behavior and migration capacity. However, it should be also 
noted that hCPCs might be representing only a group of perivascular cells, which 
tend to cluster in oxygen-rich surface regions in EHM resembling their in vivo stem 
cell niche environment.  
4.3 CPCs and fibroblasts support EHM formation 
We demonstrated that mouse and human CPCs are capable of supporting functional 
heart muscle formation in vitro similar to fibroblasts, although they seemed to not 
support functional development optimally as indicated by lower contractile 
performance in CPC-EHM vs. fibroblast-EHM. Biochemical (e.g. hormones and 
growth factors) and biophysical cues (e.g. mechanical loading, substrate stiffness 
and isotropy) play an important role in mediating cardiac function (Liaw and 
Zimmermann 2016). Biochemical factors including triiodothyronine (T3), insulin, 
growth hormone and IGF-1 as an activator of PI3K/Akt signaling pathway are among 
the particular factors involved in physiological hypertrophy and calcium homeostasis 
(Louch et al. 2015). As demonstrated from RNAseq data, hCPCs seem to have a 
different secretome profile than fibroblasts. One interesting observation, which could 
be related to the lower contractile performance in CPC-EHM, was lower IGF-1 
expression by hCPCs. In previous studies, we observed that insulin and IGF-1 can 
enhance contractile performance of EHM (Zimmermann et al. 2002); with both effects 
likely mediated via the IGF-1 receptor. Also the data on CPC optimization by 
enforced miR133-a expression, in the mouse model, suggested a important 
involvement of IGF-1 in EHM functionality and cardimoyctye survival (Izarra et al. 
2014). Thus one may conclude that CPCs have a limited paracrine activity under 
basal conditions, which can be enhanced by genetic manipulation to achieve optimal 
heart muscle support. Whether similar genetic modifications would also enhance the 




4.4 CPCs do not contribute to cardiac homeostasis under normal conditions 
Isolated CPCs require special microenvironmental conditions for the induction of 
cardiomyocyte differentiation in vitro, such as stimulation with chemicals including 
dexamethasone (Beltrami et al. 2003) and 5-azacytidine (Oh et al. 2003), growth 
factors (Goumans et al. 2007) as well as co-culturing with cardiomyocytes (Bearzi et 
al. 2007). However, hCPCs were not detected to differentiate into cardiomyocytes in 
the EHM co-culture model, as demonstrated by lack of sarcomeric α-actinin 
expression in GFP-labelled CPCs. This finding was in contrary to other studies 
describing myogenic specification of CPCs co-cultured with adult cardiomyocytes 
(Pfister et al. 2005). Obvious reasons for the failure to detect cardiomyocyte 
transdifferentiation could be: (1) hESC-derived cardiomyocytes and hFFs may not 
support CPC transdifferentiation; (2) hCPCs do not possess a cardiogenic potential.  
Cardiosphere-derived progenitors have been reported to enhance cell cycle activity 
of endogenous cardiomyocytes when injected into the myocardium after myocardial 
infarction (Malliaras et al. 2013). In addition, delivery of c-Kit+ CPCs into the infarcted 
myocardium promoted the formation of proliferative new cardiomyocytes in long-term 
(Tang et al. 2016). According to these published evidences, one of the mechanisms 
underlying cardio-regenerative effect of CPCs seems to work through induction of 
proliferation of endogenous cardiomyocytes. In contrast to this proposed mechanism, 
we did not detect any additional proliferating response in cardiomyocytes co-cultured 
with hCPCs. 
4.5 CPCs can be modified to enhance their tissue-supporting activity 
Low cell retention and engraftment are limiting factors that weaken the success of a 
cell-based therapy. Genetic modification is one of the key approaches to enhance 
delivery efficacy of transplanted cells (Terrovitis et al. 2010). Survival of CPCs after 
injection into the infarcted myocardium was studied by our collaborators (CARE-MI 
FP7 Consortium; Antonio Bernad; (Izarra, 2014 #95). Overexpression of miR133a in 
CPC enhanced their therapeutic efficacy in vivo. These observations were in line with 
reports on the ciritical role of mir-133a in stimulating cardiomyocyte proliferation 




expression did not increase CPC engraftment in vivo. In agreement with the 
enhanced therapeutic efficacy in vivo we observed an increased paracrine activity of 
mir-133a-CPCs in rat EHM. The observed reduced cardiomyocyte apoptosis in CPC-
miR133a supplemented EHM could have accounted for the improved functional 
outcome in EHM, but also in the in vivo experiments. These experiments 
demonstrate the utility of the EHM culture format in defining the mode of action in 
potential cell therapeutics. Whether the specific modification tested would only be 
effective in CPCs remain to be studied. 
4.6 Development of EHM models of hypoxic damage 
Heart muscle can undergo a temporal dysfunction, so called myocardial stunning or 
be permanently damaged leading to lethal ischemia/reperfusion injury. In addition, 
response to ischemia/reperfusion injury can also depend on the cell type and organ 
(Kalogeris et al. 2012). Although the exact mechanism that shifts from reversible 
ischemia to irreversible ischemia/reperfusion injury is not well-known, it most likely 
requires a number biochemical and metabolic changes including loss of a critical 
amount of ATP and Ca2+ overload (Rovetto et al. 1975). To develop a model system 
for ischemic heart damage, we tested different hypoxia and reoxygenation protocols 
in EHM culture. 72 hrs of hypoxia resulted in high lactate accumulation, significant 
ATP depletion and loss of HIF-1 activity in monolayer cardiomyocytes. In EHM 
culture, contractile performance was not obviously disturbed after 72 hrs of hypoxia, 
but clearly diminished after additional 24 hrs of reoxygenation. In addition to reduced 
basal force of contraction, high calcium sensitivity (suggesting calcium overload) and 
less β-adrenergic response was observed. Extended hypoxia over 120 hrs resulted in 
similar damage as observed in the 72 hrs hypoxia 24 hrs reoxygenation experiment. 
These data identify a narrow time window for the simulation of hypoxia/reperfusion 
damage in EHM. An unanticipated observation was that EHM subjected to 
hypoxia/reoxygenation injury could be partially protected from fibroblasts, but not 
CPC-conditioned medium, suggesting a protective paracrine activity in fibroblasts.  
 
RNAseq profiling identified enhanced anti-apoptotic and cell proliferation/growth 
enhancing effects in hFFs, which may explain the observed differential effect of 




angiogenesis inducing activity in hCPCs may, in the absence of the respective target 
cells, not be functional in EHM. These data collectively suggest that complex 
multicellular models are needed to fully determine the biological activity of CPCs. 
Finally, our data supports the use of animal models to fully determine the likely 
comprehensive effects of cell based therapies.  
4.7 CPCs protect EHM under chronic hypoxia 
Cardiac progenitor cell based therapy, regardless of the delivery mode, requires the 
deposition and retention (at least transiently) of CPCs in or adjacent to damaged 
myocardium, which is typically inflamed and hypoxic (Li et al. 2016). In agreement 
with the concept of cell context specific efficacy of CPCs, we developed EHM with 
the most abundant cardiac cell populations, i.e., cardiomyocyte and fibroblasts, 
supplemented with CPCs. Finally, these EHM tri-cultures were composed of 65% 
cardiomyocyte, 28% foreskin fibroblasts and 7% hCPCs to simulate a native heart 
cell composition. Interestingly, EHM tri-cultures were protected from chronic (120 hrs) 
hypoxic injury. In line with the finding in H/R injury model, hCPCs did not enhance 
survival of cardiomyocytes, but helped to maintain strucutural and functional integrity, 
suggesting that hCPCs played a critical role in the adaptation to chronic hypoxia. 
Thus far, we propose that CPCs under chronic hypoxia support a myocardial 
hibernation state (Holley et al. 2015). The underlying mechanisms, especially with 
respect to mitochondria function and metabolism, need to be studied in more detail. 
Whether a modification of hCPCs, such as enforced miR133a expression, would 
enhance the therapeutic efficacy as to a protection from cell death remains to be 
studied. 
4.8 Live cell imaging of cardiomyocyte oxygenation  
To gain further insight into the mechanisms underlying hypoxic damage and 
protection from hypoxia, including hypoxia/reoxygenation injury, it is important to on 
the one hand establish a human model and on the other hand visualize 
cardiomyocyte specific oxygenation. We first demonstrated that a recently 
established hypoxia sensor, ODD-Luc can be integrated and utilized to visualize and 




cell-derived cardiomyocytes (Hesse et al. 2014). Having the first evidence of 
applicability of ODD-Luc cardiomyocytes for imaging hypoxia in tissue level in a 
mouse EHM model, we next developed a human model that involves a human 
embryonic stem cell (hESC) line genetically modified to express ODD-Luc fusion 
protein. The preliminary data in human system first showed that cardiomyocytes 
differentiated from hESCs successfully express ODD-Luc with protein stabilization 
and thus enhanced Luc-signal under hypoxia. This indicates that it should be feasible 
to develop a human ODD-Luc EHM model for more detailed studies of the 
mechanisms underlying hypoxia associated myocardial damage as well as protection 
from hypoxic injury. 
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Engineered Heart Muscle (EHM) was established as model system for the evaluation 
of the biological activity of cardiac progenitor cells (CPCs) from mouse and human. 
Color-coding of cardiomyocytes and non-myocytes in EHM allowed for cell type 
specific morphological and molecular analyses. Interestingly, fibroblasts and CPCs, 
despite being distinct cell entities based on their molecular properties, supported 
functional assembly of EHM in a similar way. Moreover, fibroblasts, but not CPCs, 
appear to be protective in a H/R injury model. Conversely, CPCs were critical and 
supportive for the maintanence of cardiac function in EHM subjected to chronic 
hypoxia. This effect in the presence of cardiomyocytes and fibroblasts appeared cell 
context dependent. Genetic manipulation of CPCs by forced expression of miR-133a 
was established as a model system for enhanced biological activity. The ODD-Luc 
model will be instrumental not only for in vitro studies, but also to trace EHM survival 
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A1. Reagents and medium  
Reagents and medium for cell culture:  
IGF-1 stock solution 
Reconstitute IGF-1 (Recombinant Human IGF-1, #AF-100-11, Peprotech) in sterile 
1x PBS with 0.1% human recombinant serum albumin (HSA) (#A9731, Sigma-
Aldrich) according to manufacturer’s protocol to obtain a stock concentration of 100 
µg/ml; aliquots were stored at -20 °C until further use. 
bFGF stock solution (Peprotech) 
Reconstitute bFGF (Recombinant Human FGF-basic [154 a.a], #AF-100-18B, 
Peprotech) in sterile 1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to 
manufacturer’s protocol to obtain a stock concentration of 10 μg/m; aliquots were 
stored at -20 °C until further use. 
bFGF stock solution (Miltenyi Biotech) 
Reconstitute bFGF (Human FGF-2 premium grade, #130-093-841, Miltenyi Biotech) 
in sterile 1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to 
manufacturer’s protocol to obtain a stock concentration of 10 μg/ml; aliquots were 
stored at -20 °C until further use. 
VEGF-A stock solution 
Reconstitute VEGF-A (Animal-Free Recombinant Human VEGF [165], #AF-100-20, 
Peprotech) in sterile 1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to 
manufacturer’s protocol to obtain a stock concentration of 5 μg/ml; aliquots were 
stored at -20 °C until further use. 
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TGF-β1 stock solution 
Reconstitute TGF-β1 (Recombinant Human TGF-β1 [CHO cell derived], #AF-100-
21C, Peprotech) in sterile 1x PBS with 0.1% HAS (#A9731, Sigma-Aldrich) according 
to manufacturer’s protocol to obtain a stock concentration of 5 μg/ml; aliquots were 
stored at -20 °C until further use. 
EGF stock solution 
Reconstitute EGF (Animal-Free Recombinant Human EGF, #AF-100-18B, 
Peprotech) in sterile 1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to 
manufacturer’s protocol to obtain a stock concentration of 10 μg/ml; aliquots were 
stored at -20 °C until further use. 
BMP-4 stock solution 
Reconstitute BMP-4 (Recombinant Human BMP-4, #314-BP, R&D Systems) in sterile 
1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to manufacturer’s 
protocol to obtain a stock concentration of 10 μg/ml; aliquots were stored at -20 °C 
until further use. 
Activin A stock solution 
Reconstitute Activin A (Recombinant Human/Mouse/Rat Activin A Protein, #338-AC, 
R&D Systems) in sterie 1x PBS with 0.1% HSA (#A9731, Sigma-Aldrich) according to 
manufacturer’s protocol to obtain a stock concentration of 10 μg/ml; aliquots were 
stored at -20 °C until further use. 
CHIR stock solution 
Reconstitute CHIR (StemoleculeTM CHIR99021, #04-0004, Stemgent) in DMSO 
according to manufacturer’s protocol to obtain a stock concentration of 10 mmol/L; 
aliquots were stored at -20 °C until further use. 
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IWP-4 stock solution 
Reconstitute IWP-4 (StemoleculeTM Wnt Inhibitor IWP-4, #04-0036, Stemgent) in 
DMSO according to manufacturer’s protocol to obtain a stock concentration of 5 
mmol/L; aliquots were stored at -20 °C until further use. 
Nucleoside Mix (100x) 
Dissolve 80 mg Adenosine (final con. 30 µmol/L, #A4036, Sigma), 85 mg Guanosine 
(final con. 30 µmol/L, #G6264, Sigma), 73 mg Cytidine (final con. 30 µmol/L, #4654, 
Sigma), 73 mg Uridine (final con. 30 µmol/L, #U-3003, Sigma) and 24 mg Thymidine 
(final con. 10 µmol/L, #T1895, Sigma) in 1x PBS, sterile filter; aliquots were stored at 
-20 °C until further use. 
Ascorbic acid stock solution 
Dissolve 0.87 g L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (#A8960, 
Sigma-Aldrich) in 10 ml of ddH2O to obtain 300 mmol/L stock concentration, sterile 
filter; aliquots were stored at -20 °C until further use. 
CMR supplement (50x) 
 
  
Albumin Human (#A9731, Sigma-Aldrich) 1.25 g 
Triiodothyronine (T3),  10 µg  
Transferrin 25 mg  
Sodium Selenite 80 µg  
> adjust with Aq. dest. water up to 50 mL 
> keep aliquots at -20 °C. 
 
10x DMEM 
Dissolve 1.34 g DMEM powder (DMEM, powder, high glucose, #52100-039, Gibco) 
in 10 ml of ddH2O, sterile filter and keep at 4 °C.  
10x RPMI 
Dissolve 1.04 g RPMI powder (RPMI 1640 medium, powder, #52800-035, Gibco) in 
10 ml of ddH2O, sterile filter and keep at 4 °C. 
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Rat EHM medium 
 
  
Iscove's medium (#F0465, Biochrom) 500 ml 
Horse serum (#16050, Gibco) 58 ml 
Chich embryo extract 11.6 ml 
Penicilin (Pen)/Streptomycin (Strep) (100x, Pen: 







DMEM, high glucose, HEPES (#42430-025, Gibco) 500 ml 
Fetal Bovine Serum (FBS) (#10270, Gibco) 92 ml 
L-Glutamine (200 mmol/L, #25030-024, Gibco) 6.2 ml 
Pen/Strep (100x,  #15140-122, Gibco) 6.2 ml 
MEM Non-Essential Amino Acids Solution (NEAA) 
(100x, #111450-035, Gibco) 
6.2 ml 
Sodium Pyruvate (100 mmol/L, #11360-039, Gibco) 6.2 ml 
Nucleoside mix (100x) 6.2 ml 
Leukemia Inhibitory factor (LIF) (1000 Units/ml, 
#ESG1106, Esgro) 
62 µl 
2-β-mercaptoethanol (31350-010, Sigma) 4.34  µl 
  
mESC differentiation (diff.) medium / mEHM 
medium  
  
Iscove's medium (#F0465, Biochrom) 500 ml 
FBS (#10270, Gibco) 120 ml 
L-Glutamine (200 mmol/L, #25030-024, Gibco) 6.2 ml 
Pen/Strep (100x,  #15140-122, Gibco) 6.2 ml 
MEM-NEAA (100x, #111450-035, Gibco) 6.2 ml 
L-Ascorbic acid 2-phosphate sesquimagnesium salt 
hydrate (Ascorbic acid for cell culture,  #A8960, 
Sigma) 
54 mg (final concentration 
[con]: 300 µmol/L) 


















mCPC medium (incomplete) 
  
DMEM/F-12 medium (#31300-038, Gibco) 500 ml 
FBS (#10270, Gibco) 50 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5.5 ml 
L-Glutamine (200 mmol/L, #25030-024, Gibco) 5.5 ml 
Insulin-Transferrin-Selenium-Ethanolamine (ITS-X) 
(100x, # 51500-056, Gibco) 
5.5 ml 





mCPC medium (incomplete) 50 ml 
EGF stock solution 200 µl (final con: 40 ng/mL) 





DMEM medium ( #61965-026, Gibco) 500 ml 
FBS (#10270, Gibco) 50 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5.5 ml 
MEM-NEAA (100x, #111450-035, Gibco) 5.5 ml 
  
 
hCM medium  
  
RPMI medium 1640, GlutaMAX™ (#61870-010, 
Gibco) 
500 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5.2 ml 
Sodium Pyruvate (100 mM, #11360-039, Gibco) 5.2 ml 
Ascorbic acid stock solution (300 mmol/L) 333 µl 
B-27® Supplement (50x, #17504-044, Gibco) 10 ml 
  
hEHM medium (incomplete) 
 
  
Iscove's medium (#F0465, Biochrom) 500 ml 
L-Glutamine (200 mmol/L, #25030-024, Gibco) 5.5 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5.5 ml 
MEM-NEAA (100x, #111450-035, Gibco) 5.5. ml 













hEHM medium (incomplete) 50 ml 
B-27® Supplement, minus insulin (50x, #A18956-
01, Gibco) 
2 ml 
IGF-1 stock solution 50 µl (final con: 100 ng/mL) 
bFGF stock solution 50 µl (final con: 10 ng/mL) 
VEGF-A stock solution 50 µl (final con: 5 ng/mL) 
  
hEHM consolidation medium 
 
  
hEHM medium 50 ml 





DMEM, high glucose, HEPES (#42430-025, Gibco) 500 ml 
FBS (#10270, Gibco) 75 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5.8 ml 
  
DMEM SF-B27 medium 
 
  
DMEM, low glucose, GlutaMAX ™, Pyruvate 
(#21885-025, Gibco) 
500 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5 ml 
MEM-NEAA (100x, #111450-035, Gibco) 5 ml 




DMEM SF-CMR medium 
 
  
DMEM, low glucose, GlutaMAX ™, Pyruvate 
(#21885-025, Gibco) 
500 ml 
Pen/Strep (100x,  #15140-122, Gibco) 5 ml 
MEM-NEAA (100x, #111450-035, Gibco) 5 ml 
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2x Rat EHM DMEM 
  
10x DMEM 1 ml 
Horse serum ((#16050, Gibco) 1 ml 
Chick embryo extract  0.2 ml 
Pen/Strep (100x,  #15140-122, Gibco) 0.1 ml 
ddH2O 2.7 ml 
  
2x Mouse EHM DMEM 
 
  
10x DMEM 1 ml 
FBS (#10270, Gibco) 2 ml 
Pen/Strep (100x,  #15140-122, Gibco) 0.2 ml 
ddH2O 1.8 ml 
  
2x Human EHM RPMI 
 
  
10x RPMI 2 ml 
B-27® Supplement, minus insulin (50x, #A18956-
01, Gibco) 
0.8 ml 
Pen/Strep (100x,  #15140-122, Gibco) 0.2 ml 





KO DMEM medium (#10829, Invitrogen) 39.5 ml 
KSR (Knockout Serum Replacement) (#10828, 
Invitrogen) 
10 ml 
MEM-NEAA (100x, #111450-035, Gibco) 0.5 ml 
L-Glutamine (200 mmol/L, #25030-024, Gibco) 0.5 ml 
Pen/Strep (100x,  #15140-122, Gibco) 0.5 ml 
bFGF stock solution (Miltenyi Biotech) 50 µl (final con: 10 ng/mL) 
  
hFF conditioned medium 
 
  
hESC medium 50 ml 
bFGF stock solution (Miltenyi Biotech) 25 µl (final con: 5 ng/mL) 




hESC conditioned medium  
  
hESC medium 25 ml 
hFF conditioned medium 25 ml 
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Mesoderm induction medium 
  
hCM medium 50 ml 
CHIR stock solution 5 µl (final con: 1 µmol/mL) 
BMP4 stock solution 25 µl (final con: 5 ng/mL) 
Activin-A stock solution 45 µl (final con: 9 ng/mL) 
bFGF stock solution (Miltenyi Biotech) 25 µl (final con: 5 ng/mL) 
  
Cardiac specification medium 
 
  
hCM medium 50 ml 
IWP4 stock solution 50 µl (final con: 5 µmol/mL) 
  
hCM selection medium 
 
  
RPMI medium 1640, without D-Glucose, without L-
Glutamine (#01-101-1A, Biological Industries) 
49.15 ml 
Pen/Strep (100x,  #15140-122, Gibco) 0.5 ml 
Sodium DL-Lactate solution 50% in H2O (#71723, 
Sigma-Aldrich) 
0.25 ml 






hCPC-Conditioned medium (ConM) 
 
hCPCs were plated and cultured in T-25 culture flask in hFF-medium with the 
seeding density of 1 x 106 cells/flask. hFF medium was replaced with DMEM SF-
CMR medium when hCPCs reached 90-100% confluency. DMEM SF-CMR medium 
from hCPCs was collected every second day for 7 days and immediately frozen and 
stored at -80 °C. hCPC conditioned medium (ConM) was prepared freshly, diluted 
1:1 with fresh DMEM SF-CMR medium prior to use. 
 
hFF-Conditioned medium (ConM) 
 
 
hFFs were plated and cultured in T-25 culture flask in hFF-medium with the seeding 
density of 1 x 106 cells/flask. hFF medium was replaced with DMEM SF-CMR 
medium when hFFs reached 90-100% confluency. DMEM SF-CMR medium from 
hFFs was collected every second day for 7 days and immediately frozen and stored 
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at -80 °C. hFF-ConM was prepared freshly, diluted 1:1 with fresh DMEM SF-CMR 
medium prior to use. 
 
Collagenase digestion solution 
 
Dissolve 500 mg collagenase (Collagenase from Clostridium histolyticum for general 
use, Type I, # C0130, Sigma-Aldrich) in 250 ml of 1x PBS containing Ca+2 and Mg+2 
with 20% FBS (#10270, Gibco), sterile filter and keep aliquots at -20 °C. 
Dnase stock solution 
Dissolve Dnase I (DNase I, Bovine Pancreas, #260913, Calbiochem) in ddH2O to 
obtain a stock concentration of 1 mg/mL, keep aliquots at -20 °C. 
EDTA solution 
Add 500 µl of 0.5 M EDTA solution (EDTA solution pH 8.0 (0.5 M) for molecular 
biology (#A4892, AppliChem) to 500 ml of 1x PBS containing 0.45 g NaCl. Sterile 
filter, keep aliquots at 4 °C. 
EB digestion protocol 
 
  
Collagenase digestion solution 10 ml 
Dnase stock solution 200 µl 
 
hCM digestion solution  
  
Accutase cell detachment solution, (#SCR005, 
Milipore) 
97.75 ml 
Trypsin (2.5%) (#15090-046, Gibco) 0.25 ml 
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Reagents for isometric force measurement: 
CaCl2 stock solution (2.25 mol/L)  
  
CaCl2 x 2H2O (Mw: 147.02 g/mol) 165.57 g 
ddH2O 500 ml 
  
MgCl2 stock solution (1.05 mol/L) 
 
  
MgCl2 x 6H2O (Mw: 203.01 g/mol) 106.83 g 
ddH2O 500 ml 
  
Stock I solution (0.2 mmol/L Calcium) 
 
  
NaCl 175 g 
KCl 10 g 
CaCl2 stock solution (2.25 mol/L) 2.22 ml 
MgCl2 stock solution (1.05 mol/L) 25 ml 
ddH2O up to 1 L 
  
Stock II solution 
 
  
NaHCO3 50 g 
ddH2O 1 L 
  
Stock III solution 
 
  
NaH2PO4 5.8 g 
ddH2O 1 L 
  







Stock I solution (0.2 mmol/L Calcium) 200 ml 
Stock II solution 190 ml 
Stock III solution 50 ml 
D-Glucose 5 g 
Ascorbic acid 500 mg 
ddH2O up to 5 L 
 
>Prepare the Tyrode solution prior to contraction force measurement. 
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Reagents for western blot: 
 
Solutions for cell lysis: 
Protease inhibitor stock solution (10x) 
Dissolve 1 tablet of protease inhibitor (Protease inhibitor, cOmplete ULTRA Tablets, 
Mini, EASYpack, #05892970001, Roche) in 1.5 ml of ddH2O, keep in aliquots at -20 
C. 
Phosphatase inhibitor stock solution (10x) 
Dissolve 1 tablet of phosphatase inhibitor (Phosphatase inhibitor, PhosSTOP 
EASYpack, #04906837001, Roche) in 1 ml of ddH2O, keep aliquots at -20 °C. 
Cell lysis buffer (incomplete) 
 
  
Tris-HCl (pH 8.0) 10 mmol/L 
NaCl 400 mmol/L 
EDTA 1 mmol/L 
> keep at 4 °C. 
 
  
Cell lysis buffer 
 
  
Cell lysis buffer (incomplete) 750 µl 
Protease inhibitor stock solution 
(10x) 
150 µl 




Solutions for SDS-gel electrophoresis: 
0.5 mol/L Tris-HCl pH 6.8 
 
  
Tris-HCl 30.28 g 
ddH2O 500 ml 
> adjust to pH 6.8. 
 
  
1.5 mol/L Tris-HCl pH 8.8 
 
  
Tris-HCl 90.85 g 
ddH2O 500 ml 
> adjust to pH 8.8. 
 





Solutions for immunoblotting: 
Transfer buffer (10x) 
 
  Tris-Base 60.5 g 
Glycine 288 g 






Laemmli loading buffer (6x) 
 
  
0.5 mol/L Tris-HCl pH 6.8 3 ml 
Bromphenol blue 0.5% 0.75 ml 
SDS 1.2 g 
Glycerin 100% 1.5 ml 
2-β-Mercaptoethanol 150 µl 
ddH2O up to 10 ml 
> keep aliquots at -20 °C. 
 
  
Seperating gel (12%, 2 gels) 
 
  
ddH2O 3.3 ml 
Acrylamide 30% 4 ml 
1.5 mol/L Tris-HCl pH 8.8 2.5 ml 
SDS 10% 100 µl 
APS 10% 100 µl 
TEMED 4 µl 
  
Stacking gel (2 gels) 
 
  
ddH2O 2.8 ml 
Acrylamide 30% 0.85 ml 
0.5 mol/L Tris-HCl pH 6.8 1.25 ml 
SDS 10% 50 µl 
APS 10% 50 µl 
TEMED 5 µl 
  
 
Running buffer (10X, pH 8.3-8.7)  
  
Tris-Base 30.3 g 
Glycine 144.1 g 
ddH2O 1 L 
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Transfer buffer (1x) 
  Transfer buffer (10x) 100 ml 
Methanol 200 ml 
ddH2O up to 1 L 
 
Blocking buffer 
Prepare 5% of milk powder (milk, non-fatty dried, Carl Roth) solution in 1x PBS. 
 
Reagents for Agarose gel electrophoresis: 
TAE buffer (50x) 
 
  Tris-Base 242.2 g 
0.5 M EDTA pH 8.0 18.6 g 
Acetic acid 57.1 g 
ddH2O up to 1 L 
> adjust to pH 8.5. 
 
  TAE buffer (1x) 
 
  TAE buffer (50x) 3 ml 
ddH2O up to 150 ml 
  Agarose gel (1.5%) 
 
  TAE buffer (1x) 100 ml 
Agarose UltraPureTM (AppliChem) 1.5 g 
 
> Let the agarose gel cool down, pipette 0.2 µg/ml ethidium bromide (EtBR; Ethidium 
bromide solution, #46067, Sigma-Aldrich) into the gel and directly pour into the 
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Reagents for Immunostaining: 
Permeabilizing blocking buffer for Immunocyto/histostaining and Flow cytometry 
Goat serum  26.3 ml 
Bovine serum albumin (BSA) (#A3311, Sigma) 5.26 g 
Triton x-100  2.63 ml 
1x PBS up to 500 ml 
 
Non-permeabilizing blocking buffer for Flow cytometry 
Prepare 1x PBS containing 5% FBS (#10270, Gibco) and keep at 4 °C until use. 












rev GAACTCTTGCCCACATCGTT  






























          
human PECAM1 
fwd GGTGGAAGGAGTGCCCAG T 
114 ENSG00000261371 
rev GTGAAGTGTATTGGGGCCTTT 






























          
human VEGFA fwd CACGAAGTGGTGAAGTTCATGG 121 ENSG00000112715 



















          
human GAPDH 
fwd 




rev ATG TTC TGG AGA GCC CCG C   





rev GCTTCTTGTAGT CGGGGATG   
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A3. Antibodies and dyes 
 
    
Dilution amount 
Primary antibody Species Manufacturer Cat. # Flow cytometry Whole mount WB 
Anti-CD117-PE rat Miltenyi Biotec 130-091-730 1:33  − − 
Anti-CD140a (PDGFRα)-PE  rat eBioscience 12-1401 1:500  − − 
Anti-CD105-APC  rat Miltenyi Biotec 130-092-930  1:11 − − 
Anti-Sca-1-PE rat Miltenyi Biotec 130-102-832  1:33 − − 
Anti-CD117-BV421  mouse BD Horizon™  562434  1:20 − − 
Anti-CD31-FITC mouse BD Pharmingen 557508  1:20 − − 
Anti-CD31-BV510  mouse BD Horizon™  563454  1:20 − − 
Anti-CD90-BUV395,  mouse BD Horizon™  563804  1:20 − − 
Anti-CD105-PerCp-Cy 5.5  mouse BD Horizon™  560819  1:20 − − 
Anti-CD45-FITC mouse BD Pharmingen 555482  1:20 − − 
Anti-α-Actinin (Sarcomeric)  mouse Sigma-Aldrich A7811  1:4000 1:1000  − 
Anti-Ki67 rabbit Thermoscientific RM-9106-S0  1:50 1:200  − 
Anti-active caspase-3 rabbit Promega G748 −  1:250 − 
Anti-GFP  rabbit Abcam ab290 −  1:500 − 
Anti-HIF-1α mouse BD Transduction 610959 − −  1:1000 
Anti-β-actin mouse Sigma-Aldrich A2228 − −  1:5000 
 
    
Dilution amount 
Secondary antibody Species Manufacturer Cat. # Flow cytometry Whole mount WB 
anti-mouse-Alexa Fluor 488 goat Invitrogen A11001 1:1000  1:1000 − 
anti-mouse-Alexa Fluor 546 goat Invitrogen A11003  1:1000 1:1000 − 
anti-mouse-Alexa Fluor 633 goat Invitrogen A-21050  1:1000 1:1000 − 
Anti-mouse-IgG-HRP conjugated mouse Dako P0260 − − 1:10000 
 
   
Dilution amount 
Dye Manufacturer Cat. # Flow cytometry Whole mount 
Hoechst, 1 mg/ml BD Biosciences 33342 1:1000 1:1000 
Sytox Red Dead Cell Stain-633 Molecular Probes S34859 1:1000 1:1000 
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A4. Life organisms 
 
Animals: 
Species Background Source 





knock-in in ROSA26 locus, expression  enhanced by fusion to 
a CMV promoter element  
The Jackson laboratory 
Rattus norvegicus Wistar Animal facility, UMG 
 
Cell lines: 
Cell line Genetic background Source 
mESCs-αMHC-NeoR 
mESC-R1 line (Nagy et al. 1993) with random 
integration of neoR gene under transcriptional control 
by cardiomyocyte specific αMHC promoter element 




Transgenic ROSA26 ODD-Luc/+ mice derived mESCs 
ubiquitiously expressing HIF-1α-ODD-Luc fusion 
protein and neomycin resistance (neoR) under 
transciptional control by αMHC promoter element) 
Isolation and transgenic 
modification of the stem cell line 
by Andreas Schraut (Institute of 




Mouse cardiac progenitor cells isolated from adult 
mouse heart with retrovirus transduction of EGFP 
Kindly provided by Mark 




Human cardiac progenitor cells isolated from atrial 
appendage of adult human heart with lentiviral 
transduction of EGFP 
Kindly provided by Coretherapix 




Human foreskin fibroblasts with lentiviral transduction 
of EGFP 
wild type hFFs; ATCC, #SCRC-
1041  
hES2 RFP 
HES2 line (Embryonic Stem cell International) 
(Reubinoff et al. 2000) with tdRFP knock-in in ROSA26 
locus 
Kind gift by Gordon Keller (Irion 
et al. 2007) 
hES2-HIF-1α-ODD-
Luc 
HES2 line with random integration of HIF-1α-ODD-Luc 
fusion protein under Cytomegalovirus (CMV) promoter 
element  
Trangenic modification of the 
stem cell line by Dr. Claudia 
Noack and Krasimira Sharkova 
Other cell types Genetic background Source 
mEFs NMRI mice See section 2.2.3  
mCM 
Mouse cardiomyocytes from mESC-HIF-1α-ODD-
Luc/αMHC-neoR 
See section 2.1.2 
hCM Human cardiomyocytes from hES2 RFP See section 2.1.3 
ODD-Luc hCM 
Human cardiomyocytes from hES2 RFP-HIF-1α-ODD-
Luc 
See section 2.7.5 
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A5. Human CPC specific differentially expressed genes 
 
Table 17. Differentially expressed plasma membrane genes in hCPCs compared to hCFs and 
hFFs. 
Gene symbol Gene Name 
HTR1D 5-hydroxytryptamine (serotonin) receptor 1D 
HTR1F 5-hydroxytryptamine (serotonin) receptor 1F 




A kinase (PRKA) anchor protein 2; paralemmin 2; PALM2-AKAP2 readthrough transcript 
ADAM29 ADAM metallopeptidase domain 29 
ART1 ADP-ribosyltransferase 1 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 
ATP4A ATPase, H+/K+ exchanging, alpha polypeptide 
CD22 CD22 molecule 
CASS4 Cas scaffolding protein family member 4 
DSCAM Down syndrome cell adhesion molecule 
EGFLAM EGF-like, fibronectin type III and laminin G domains 
EHD1 EH-domain containing 1 
EHD2 EH-domain containing 2 
EPHB6 EPH receptor B6 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 
GPR34 G protein-coupled receptor 34 
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 
GPR39 G protein-coupled receptor 39 
GPR4 G protein-coupled receptor 4 
GPR65 G protein-coupled receptor 65 
INADL InaD-like (Drosophila) 
LIMS1 LIM and senescent cell antigen-like domains 1 
MICB MHC class I polypeptide-related sequence B 
NOX4 NADPH oxidase 4 
NCKAP1L NCK-associated protein 1-like 
NOTCH4 Notch homolog 4 (Drosophila) 
RAB13 RAB13, member RAS oncogene family; similar to hCG24991 
RAB17 RAB17, member RAS oncogene family 
RAB3A RAB3A, member RAS oncogene family 
RAB43 RAB43, member RAS oncogene family; hypothetical LOC100131426 
RHD Rh blood group, D antigen 
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 
ARHGAP26 Rho GTPase activating protein 26 
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ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 
SHKBP1 SH3KBP1 binding protein 1 
TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
VSIG2 V-set and immunoglobulin domain containing 2 
ADI1 acireductone dioxygenase 1 
AFAP1 actin filament associated protein 1 
ACVRL1 activin A receptor type II-like 1 
ARC activity-regulated cytoskeleton-associated protein 
ADCY3 adenylate cyclase 3 
ALK anaplastic lymphoma receptor tyrosine kinase 
ANK1 ankyrin 1, erythrocytic 
ARSA arylsulfatase A 
ASGR1 asialoglycoprotein receptor 1 
ROS1 c-ros oncogene 1 , receptor tyrosine kinase 
CDH4 cadherin 4, type 1, R-cadherin (retinal) 
CDH24 cadherin-like 24 
CABP1 calcium binding protein 1 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 
CA2 carbonic anhydrase II 
CADM1 cell adhesion molecule 1 
CCR10 chemokine (C-C motif) receptor 10 
CCR7 chemokine (C-C motif) receptor 7 
CHRM4 cholinergic receptor, muscarinic 4 
CHRNA1 cholinergic receptor, nicotinic, alpha 1 (muscle) 
CHRNA9 cholinergic receptor, nicotinic, alpha 9 
CSPG5 chondroitin sulfate proteoglycan 5 (neuroglycan C) 
CLTCL1 clathrin, heavy chain-like 1 
CLDN2 claudin 2 
CLDN24 claudin-24-like 
F2RL3 coagulation factor II (thrombin) receptor-like 3 
COL13A1 collagen, type XIII, alpha 1 
COL23A1 collagen, type XXIII, alpha 1 
COL25A1 collagen, type XXV, alpha 1 
CPLX4 complexin 4 
CNTNAP1 contactin associated protein 1 
CTTNBP2 cortactin binding protein 2 
DDN dendrin 
DRD4 dopamine receptor D4 
EDA ectodysplasin A 
ESAM endothelial cell adhesion molecule 
EFNB1 ephrin-B1 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 
ESR1 estrogen receptor 1 
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FGA fibrinogen alpha chain 
FLT4 fms-related tyrosine kinase 4 
FUT1 fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase, H blood group) 
GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 
GABRR2 gamma-aminobutyric acid (GABA) receptor, rho 2 
GJB2 gap junction protein, beta 2, 26kDa 
GJC2 gap junction protein, gamma 2, 47kDa 
GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 
GRIK2 glutamate receptor, ionotropic, kainate 2 
GRM2 glutamate receptor, metabotropic 2 
GRM6 glutamate receptor, metabotropic 6 
ENPEP glutamyl aminopeptidase (aminopeptidase A) 
GLRA3 glycine receptor, alpha 3 
GHR growth hormone receptor 
GNG2 guanine nucleotide binding protein (G protein), gamma 2 
GNG4 guanine nucleotide binding protein (G protein), gamma 4 
GNGT2 guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2 
GBP2 guanylate binding protein 2, interferon-inducible 
HBEGF heparin-binding EGF-like growth factor 
HRH2 histamine receptor H2 
HAS1 hyaluronan synthase 1 
IGSF9 immunoglobulin superfamily, member 9 
INPP5E inositol polyphosphate-5-phosphatase, 72 kDa 
IGF1R insulin-like growth factor 1 receptor 
ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
ITGA8 integrin, alpha 8 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 
ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 
IL12RB2 interleukin 12 receptor, beta 2 
IL15 interleukin 15 
IL6 interleukin 6 (interferon, beta 2) 
KLHL17 kelch-like 17 (Drosophila) 
LZTS1 leucine zipper, putative tumor suppressor 1 
LILRB3 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 
LTK leukocyte receptor tyrosine kinase 
LIN7A lin-7 homolog A (C. elegans) 
LRP1 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
LRP2 low density lipoprotein-related protein 2 
LHCGR luteinizing hormone/choriogonadotropin receptor 
LAG3 lymphocyte-activation gene 3 
MSR1 macrophage scavenger receptor 1 
HLA-DOA major histocompatibility complex, class II, DO alpha 
MMP14 matrix metallopeptidase 14 (membrane-inserted) 
MMP25 matrix metallopeptidase 25 
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MTNR1A melatonin receptor 1A 
MPP2 membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) 
MPP7 membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) 
MAPK8IP3 mitogen-activated protein kinase 8 interacting protein 3 
MUC1 mucin 1, cell surface associated 
MYO7A myosin VIIA 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 
MYH9 myosin, heavy chain 9, non-muscle 
NRG1 neuregulin 1 
NRXN1 neurexin 1 
NCF2 neutrophil cytosolic factor 2 
NEXN nexilin (F actin binding protein) 
OSM oncostatin M 
OPCML opioid binding protein/cell adhesion molecule-like 
PARD6B par-6 partitioning defective 6 homolog beta (C. elegans) 
PARVG parvin, gamma 
PTCH2 patched homolog 2 (Drosophila) 
PHEX phosphate regulating endopeptidase homolog, X-linked 
PDE4A phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila) 
PLA2G4F phospholipase A2, group IVF 
PHKA1 phosphorylase kinase, alpha 1 pseudogene 1; phosphorylase kinase, alpha 1 (muscle) 
PODXL podocalyxin-like 
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) 
PKD1 polycystic kidney disease 1 (autosomal dominant) 
KCNN3 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 
KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 
KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 
KCNMB4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 
KCNS2 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 
KCNG1 potassium voltage-gated channel, subfamily G, member 1 
PRR7 proline rich 7 (synaptic) 
PTGER1 prostaglandin E receptor 1 (subtype EP1), 42kDa 
PTPN3 protein tyrosine phosphatase, non-receptor type 3 
PTPRF protein tyrosine phosphatase, receptor type, F 
PTPRH protein tyrosine phosphatase, receptor type, H 
PCDH11X protocadherin 11 X-linked 
PCDH12 protocadherin 12 
PCDHB15 protocadherin beta 15 
P2RY1 purinergic receptor P2Y, G-protein coupled, 1 
RHOF ras homolog gene family, member F (in filopodia) 
RHOG ras homolog gene family, member G (rho G) 
RAMP1 receptor (G protein-coupled) activity modifying protein 1 
RAMP2 receptor (G protein-coupled) activity modifying protein 2 
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ROR2 receptor tyrosine kinase-like orphan receptor 2 
RAPSN receptor-associated protein of the synapse 
RIMS3 regulating synaptic membrane exocytosis 3 
RXFP3 relaxin/insulin-like family peptide receptor 3 
ROM1 retinal outer segment membrane protein 1 
SGCA sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) 
SELP selectin P (granule membrane protein 140kDa, antigen CD62) 
SIRPB1 signal-regulatory protein beta 1 
SIT1 signaling threshold regulating transmembrane adaptor 1 
MLLT4 
similar to Afadin (Protein AF-6); myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4 
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 
SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 
SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 
SLC16A7 solute carrier family 16, member 7 (monocarboxylic acid transporter 2) 
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 
SLC2A9 solute carrier family 2 (facilitated glucose transporter), member 9 
SLC22A13 solute carrier family 22 (organic anion transporter), member 13 
SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5 
SLC25A4 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 
SLC26A9 solute carrier family 26, member 9 
SLC28A1 solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 
SLC6A13 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 
SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 
SLC7A9 solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
SLC9A1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 
SLC9A3R2 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 2 
SORBS3 sorbin and SH3 domain containing 3 
S1PR3 sphingosine-1-phosphate receptor 3 
STOM stomatin 
STX3 syntaxin 3 
TLN1 talin 1 
TNS4 tensin 4 
TBXA2R thromboxane A2 receptor 
TPO thyroid peroxidase 
TRHR thyrotropin-releasing hormone receptor 
TFRC transferrin receptor (p90, CD71) 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 
TGM3 transglutaminase 3 (E polypeptide, protein-glutamine-gamma-glutamyltransferase) 
TRPC5 transient receptor potential cation channel, subfamily C, member 5 
TRPM2 transient receptor potential cation channel, subfamily M, member 2 
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TM4SF1 transmembrane 4 L six family member 1 
TMPRSS9 transmembrane protease, serine 9 
TMEM204 transmembrane protein 204 
TNF tumor necrosis factor (TNF superfamily, member 2) 
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 
TNFSF8 tumor necrosis factor (ligand) superfamily, member 8 
VASP vasodilator-stimulated phosphoprotein 
VEPH1 ventricular zone expressed PH domain homolog 1 (zebrafish) 
VAMP1 vesicle-associated membrane protein 1 (synaptobrevin 1) 
XIRP1 xin actin-binding repeat containing 1 
ZAP70 zeta-chain (TCR) associated protein kinase 70kDa 
ZYX zyxin 
 
Table 18. Differentially expressed cell adhesion genes in hCPCs compared to hCFs and hFFs. 
Gene symbol Gene Name 
ADAM22 ADAM metallopeptidase domain 22 
AEBP1 AE binding protein 1 
CD22 CD22 molecule 
CUZD1 CUB and zona pellucida-like domains 1 
CASS4 Cas scaffolding protein family member 4 
CDON Cdon homolog (mouse) 
DSCAM Down syndrome cell adhesion molecule 
LIMS1 LIM and senescent cell antigen-like domains 1 
RAB13 RAB13, member RAS oncogene family; similar to hCG24991 
RADIL Ras association and DIL domains 
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
WISP2 WNT1 inducible signaling pathway protein 2 
AOC3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 
BMP1 bone morphogenetic protein 1 
CDH16 cadherin 16, KSP-cadherin 
CDH4 cadherin 4, type 1, R-cadherin (retinal) 
CDH23 cadherin-like 23 
CDH24 cadherin-like 24 
CLSTN2 calsyntenin 2 
CPXM1 carboxypeptidase X (M14 family), member 1 
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 
CADM1 cell adhesion molecule 1 
CADM4 cell adhesion molecule 4 
CLDN2 claudin 2 
COL6A3 collagen, type VI, alpha 3 
COL13A1 collagen, type XIII, alpha 1 
COL20A1 collagen, type XX, alpha 1 
COL27A1 collagen, type XXVII, alpha 1 
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CNTN3 contactin 3 (plasmacytoma associated) 
CNTNAP1 contactin associated protein 1 
CNTNAP2 contactin associated protein-like 2 
CYR61 cysteine-rich, angiogenic inducer, 61 
DPT dermatopontin 
DAB1 disabled homolog 1 (Drosophila) 
EDA ectodysplasin A 
EMILIN1 elastin microfibril interfacer 1 
ESAM endothelial cell adhesion molecule 
EFNB1 ephrin-B1 
FBLN7 fibulin 7 
FPR2 formyl peptide receptor 2 
HES1 hairy and enhancer of split 1, (Drosophila) 
HAS1 hyaluronan synthase 1 
ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
ITGA8 integrin, alpha 8 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 
ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 
IL32 interleukin 32 
LAMA1 laminin, alpha 1 
LAMA2 laminin, alpha 2 
LSAMP limbic system-associated membrane protein 
MCAM melanoma cell adhesion molecule 
MTSS1 metastasis suppressor 1 
MAG myelin associated glycoprotein 
MYH9 myosin, heavy chain 9, non-muscle 
NPHP4 nephronophthisis 4 
NRXN1 neurexin 1 
NFASC neurofascin homolog (chicken) 
NLGN2 neuroligin 2 
NLGN4Y neuroligin 4, Y-linked 
NRP2 neuropilin 2 
NTM neurotrimin 
OPCML opioid binding protein/cell adhesion molecule-like 
PARVG parvin, gamma 
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) 
PKD1 polycystic kidney disease 1 (autosomal dominant) 
PSTPIP1 proline-serine-threonine phosphatase interacting protein 1 
PTPRF protein tyrosine phosphatase, receptor type, F 
PCDH11X protocadherin 11 X-linked 
PCDH12 protocadherin 12 
PCDHB15 protocadherin beta 15 
PCDHGA11 protocadherin gamma subfamily A, 11 
PCDHGA5 protocadherin gamma subfamily A, 5 
Appendix (A5. Human CPC specific differentially expressed genes) 
142 
 
PCDHGA6 protocadherin gamma subfamily A, 6 
PCDHGA7 protocadherin gamma subfamily A, 7 
PCDHGA8 protocadherin gamma subfamily A, 8 
PCDHGB2 protocadherin gamma subfamily B, 2 
PCDHGB3 protocadherin gamma subfamily B, 3 
PCDHGB4 protocadherin gamma subfamily B, 4 
PCDHGB6 protocadherin gamma subfamily B, 6 
PCDHGC5, 
PCDHGC3 
protocadherin gamma subfamily C, 5 
ROR2 receptor tyrosine kinase-like orphan receptor 2 
RELN reelin 
ROM1 retinal outer segment membrane protein 1 
RS1 retinoschisin 1 
SCARF2 scavenger receptor class F, member 2 
SELP selectin P (granule membrane protein 140kDa, antigen CD62) 
MLLT4 
similar to Afadin (Protein AF-6); myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 4 
SORBS3 sorbin and SH3 domain containing 3 
SPACA4 sperm acrosome associated 4 
SNED1 sushi, nidogen and EGF-like domains 1 
THBS4 thrombospondin 4 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 
TNF tumor necrosis factor (TNF superfamily, member 2) 
ZYX zyxin 
 
Table 19. Differentially expressed genes involved in actin cytoskeleton organization in hCPCs 
compared to hCFs and hFFs. 
Gene symbol Gene Name 
CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 
EHD2 EH-domain containing 2 
NCK2 NCK adaptor protein 2 
NUAK2 NUAK family, SNF1-like kinase, 2 
PDLIM7 PDZ and LIM domain 7 (enigma) 
ARHGAP26 Rho GTPase activating protein 26 
ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 
WIPF1 WAS/WASL interacting protein family, member 1 
ACTC1 actin, alpha, cardiac muscle 1 
ACTN4 actinin, alpha 4 
ALDOA aldolase A, fructose-bisphosphate 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
DAAM2 dishevelled associated activator of morphogenesis 2 
DBN1 drebrin 1 
EPB41 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 
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EPB41L3 erythrocyte membrane protein band 4.1-like 3 
FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) 
FLNA filamin A, alpha (actin binding protein 280) 
FLNB filamin B, beta (actin binding protein 278) 
FOXJ1 forkhead box J1 
FMNL3 formin-like 3 
GHRL ghrelin/obestatin prepropeptide 
GHSR growth hormone secretagogue receptor 
INF2 inverted formin, FH2 and WH2 domain containing 
MTSS1 metastasis suppressor 1 
MYO9B myosin IXB 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 
MYH9 myosin, heavy chain 9, non-muscle 
NPHP4 nephronophthisis 4 
PLEK2 pleckstrin 2 
RHOF ras homolog gene family, member F (in filopodia) 
RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 
SPTBN5 spectrin, beta, non-erythrocytic 5 
TLN1 talin 1 
TMSB10 thymosin beta 10 
VASP vasodilator-stimulated phosphoprotein 
XIRP1 xin actin-binding repeat containing 1 
 
Table 20. Differentially expressed extracellular region genes in hCPCs compared to hCFs and 
hFFs. 
Gene symbol Gene Name 
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 
ADAMTSL4 ADAMTS-like 4 
ADAMTSL5 ADAMTS-like 5 
C1QTNF2 C1q and tumor necrosis factor related protein 2 
CD248 CD248 molecule, endosialin 
CMTM4 CKLF-like MARVEL transmembrane domain containing 4 
CMTM7 CKLF-like MARVEL transmembrane domain containing 7 
TIMP1 TIMP metallopeptidase inhibitor 1 
ACHE acetylcholinesterase (Yt blood group) 
AHSG alpha-2-HS-glycoprotein 
ANGPTL2 angiopoietin-like 2 
ANGPTL3 angiopoietin-like 3 
APOB apolipoprotein B (including Ag(x) antigen) 
APOC1 apolipoprotein C-I 
BMP5 bone morphogenetic protein 5 
BCAN brevican 
CDH13 cadherin 13, H-cadherin (heart) 
Appendix (A5. Human CPC specific differentially expressed genes) 
144 
 
CPB2 carboxypeptidase B2 (plasma) 
CP ceruloplasmin (ferroxidase) 
CCL2 chemokine (C-C motif) ligand 2 
CCL7 chemokine (C-C motif) ligand 7 
CXCL5 chemokine (C-X-C motif) ligand 5 
COL6A6 collagen type VI alpha 6 
COL4A6 collagen, type IV, alpha 6 
COL9A2 collagen, type IX, alpha 2 
COL9A3 collagen, type IX, alpha 3 
COL7A1 collagen, type VII, alpha 1 
COL8A2 collagen, type VIII, alpha 2 
COL14A1 collagen, type XIV, alpha 1 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
CFD complement factor D (adipsin) 
CFI complement factor I 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 
CRLF1 cytokine receptor-like factor 1 
ELN elastin 
EMILIN3 elastin microfibril interfacer 3 
EDN1 endothelin 1 
ECM1 extracellular matrix protein 1 
ECM2 extracellular matrix protein 2, female organ and adipocyte specific 
FBN2 fibrillin 2 
FGB fibrinogen beta chain 
FJX1 four jointed box 1 (Drosophila) 
GSN gelsolin (amyloidosis, Finnish type) 
GPC1 glypican 1 
GRN granulin 
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
GDF7 growth differentiation factor 7 
HAPLN3 hyaluronan and proteoglycan link protein 3 
IGFBP1 insulin-like growth factor binding protein 1 
IGFBP5 insulin-like growth factor binding protein 5 
IBSP integrin-binding sialoprotein 
ICAM1 intercellular adhesion molecule 1 
IL24 interleukin 24 
IL33 interleukin 33 
IL4 interleukin 4 
LAMA4 laminin, alpha 4 
LAMB3 laminin, beta 3 
LEFTY1 left-right determination factor 1 
LIF leukemia inhibitory factor (cholinergic differentiation factor) 
LOX lysyl oxidase 
LOXL4 lysyl oxidase-like 4 
MGP matrix Gla protein 
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MMP16 matrix metallopeptidase 16 (membrane-inserted) 
METRN meteorin, glial cell differentiation regulator 
NPPB natriuretic peptide precursor B 
NENF neuron derived neurotrophic factor 
OSTN osteocrin 
OGN osteoglycin 
PDGFC platelet derived growth factor C 
PTN pleiotrophin 
PMCH pro-melanin-concentrating hormone 
PCSK5 proprotein convertase subtilisin/kexin type 5 
PCSK6 proprotein convertase subtilisin/kexin type 6 
PRSS36 protease, serine, 36 
SELE selectin E 
SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 
SFTPB surfactant protein B 
TNXB tenascin XB; tenascin XA pseudogene 
THSD4 thrombospondin, type I, domain containing 4 
TGFB2 transforming growth factor, beta 2 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
VCAM1 vascular cell adhesion molecule 1 
VEGFC vascular endothelial growth factor C 
VIT vitrin 
VTN vitronectin 
WNT16 wingless-type MMTV integration site family, member 16 
WNT5A wingless-type MMTV integration site family, member 5A 
WNT7A wingless-type MMTV integration site family, member 7A 
WNT9A wingless-type MMTV integration site family, member 9A 
ZP3 zona pellucida glycoprotein 3 (sperm receptor) 





A6. Growth factors and cytokines differentially expressed in hCPCs and hFFs 
 
Table 21. hCPC specific up-regulated growth factors and cytokines compared to hFFs. 
Gene symbol Gene name 
FGF1 Fibroblast Growth Factor 1 (Acidic) 
IL15 Interleukin 15 
PDGFA Platelet-Derived Growth Factor Alpha Polypeptide 
TYMP Thymidine Phosphorylase 
TNFSF9 Tumor Necrosis Factor (Ligand) Superfamily, Member 9 
TGFB3 Transforming Growth Factor, Beta 3 
ANGPT2 Angiopoietin 2 
CFP Complement Factor Properdin 
IL17B Interleukin 17B 
TNFSF10 Tumor Necrosis Factor (Ligand) Superfamily, Member 10 
IL13 Interleukin 13 
TNF Tumor Necrosis Factor 
FGF8 Fibroblast Growth Factor 8 (Androgen-Induced) 
IFNA8 Interferon, Alpha 8 
BMP8A Bone Morphogenetic Protein 8a 
LHB Luteinizing Hormone Beta Polypeptide 
FGF16 Fibroblast Growth Factor 16 
IL18BP Interleukin 18 Binding Protein 
CFHR3 Complement Factor H-Related 3 
IL16 Interleukin 16 
IL18 Interleukin 18 
PDGFB Platelet-Derived Growth Factor Beta Polypeptide 
TNFSF8 Tumor Necrosis Factor (Ligand) Superfamily, Member 8 
ERAP1 Endoplasmic Reticulum Aminopeptidase 1 
MDK Midkine (Neurite Growth-Promoting Factor 2) 
IL32 Interleukin 32 
GDNF Glial Cell Derived Neurotrophic Factor 
PGF Placental Growth Factor 
HBEGF Heparin-Binding EGF-Like Growth Factor 
BMP1 Bone Morphogenetic Protein 1 
CXCL3 Chemokine (C-X-C Motif) Ligand 3 
JAG1 Jagged 1 
TGFB1 Transforming Growth Factor, Beta 1 
IL1A Interleukin 1, Alpha 
CFH Complement Factor H 
IL1B Interleukin 1, Beta 
CXCL12 Chemokine (C-X-C Motif) Ligand 12 
VEGFA Vascular Endothelial Growth Factor A 
IL6 Interleukin 6 
CXCL8 Chemokine (C-X-C Motif) Ligand 8 
CXCL1 
Chemokine (C-X-C Motif) Ligand 1 (Melanoma Growth Stimulating 
Activity, Alpha) 
 






Table 22. hFF specific up-regulated growth factors and cytokines compared to hCPCs. 
Gene symbol Gene name 
FGF13 Fibroblast Growth Factor 13 
IGF1 Insulin-Like Growth Factor 1 (Somatomedin C) 
CCL4 Chemokine (C-C Motif) Ligand 4 
CCL3L3 Chemokine (C-C Motif) Ligand 3-Like 3 
IL19 Interleukin 19 
NRG2 Neuregulin 2 
FIGF C-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D) 
GRP Gastrin-Releasing Peptide 
CRH Corticotropin Releasing Hormone 
EGF Epidermal Growth Factor 
CXCL11 Chemokine (C-X-C Motif) Ligand 11 
TGFA Transforming Growth Factor, Alpha 
CYTL1 Cytokine-Like 1 
CCL28 Chemokine (C-C Motif) Ligand 28 
TNFSF18 umor Necrosis Factor (Ligand) Superfamily, Member 18 
CXCL14 Chemokine (C-X-C Motif) Ligand 14 
CCL3 Chemokine (C-C Motif) Ligand 3 
PDGFD Platelet Derived Growth Factor D 
IL34 Interleukin 34 
CSF2 Colony Stimulating Factor 2 (Granulocyte-Macrophage) 
CXCL10 Chemokine (C-X-C Motif) Ligand 10 
BMP2 Bone Morphogenetic Protein 2 
HGF Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor) 
SPP1 Secreted Phosphoprotein 1 
NTF3 Neurotrophin 3 
TM7SF2 Transmembrane 7 Superfamily Member 2 
KITLG KIT Ligand 
EREG Epiregulin 
BDNF Brain-Derived Neurotrophic Factor 
ANGPT1 Angiopoietin 1 
VEGFC Vascular Endothelial Growth Factor C 
CCL2 Chemokine (C-C Motif) Ligand 2 
GDF15 Growth Differentiation Factor 15 
CSF1 Colony Stimulating Factor 1 (Macrophage) 
FGF2 Fibroblast Growth Factor 2 (Basic) 
GRN Granulin 
 
 
 
 
